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Protein degradationThe ubiquitin–proteasome system (UPS) is the primary selective degradation system in the nuclei and cytoplasm of
eukaryotic cells, required for the turnover ofmyriad soluble proteins. The hundreds of factors that comprise the UPS
include an enzymatic cascade that tags proteins for degradation via the covalent attachment of a poly-ubiquitin
chain, and a large multimeric enzyme that degrades ubiquitinated proteins, the proteasome. Protein degradation
by the UPS regulates many pathways and is a crucial component of the cellular proteostasis network. Dysfunction
of the ubiquitination machinery or the proteolytic activity of the proteasome is associated with numerous human
diseases. In this review we discuss the contributions of the proteasome to human pathology, describe mechanisms
that regulate the proteolytic capacity of the proteasome, anddiscuss strategies tomodulate proteasome function as a
therapeutic approach to ameliorate diseases associated with altered UPS function. This article is part of a Special
Issue entitled: Ubiquitin–Proteasome System. Guest Editors: Thomas Sommer and Dieter H. Wolf.
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The cellular protein pool is in constant ﬂux. Its composition is deﬁned
by the proteostasis network, comprised of ribosomes, chaperones and
two proteolytic systems, the lysosome and UPS [1]. These adaptable sys-
tems sustain protein homeostasis under a large variety of different condi-
tions such as during oxidative stress, cellular differentiation, varying
nutrient supply, exposure to elevated or reduced temperature, and xeno-
biotic stress. The activities of the different components of the proteostasis
network are functionally linked and compensatory strategies are in place
to avoid proteostasis collapse if the activity of one ormore of the network
components declines. Failure or malfunction of the proteostasis network
is often associated with human disease [1]. Modulating proteostasis has
therefore emerged as a promising new avenue for the development of
treatments for diverse diseases such as cancer, neurodegeneration, auto-
immunity, cardiomyopathy, inherited diseases caused by partial loss of
functionmutations, such as cysticﬁbrosis, and inheriteddiseases associat-
ed with protein misfolding and toxic gain of function.
The UPS is the primary degradation system that mediates the degra-
dation of short-lived regulatory proteins and the removal of damaged
soluble proteins. The recognition signal for proteasomal degradation is
a ubiquitin chain covalently attached to lysine residues in substrate pro-
teins. Formation of an isopeptide bond between the ε-amino group ofitin–Proteasome System. Guest
1 718 430 8565.
1 617 432 1144.
. Schmidt),
ights reserved.substrate lysines and the carboxyl group of the C-terminal glycine of
ubiquitin is an ATP-dependent process and is achieved via an enzymatic
cascade involving three distinct classes of enzymes: ubiquitin-activating
enzymes (E1), ubiquitin-conjugating enzymes (E2) and ubiquitin li-
gases (E3) [2]. The same reaction links additional ubiquitin molecules
to the primary ubiquitin via internal ubiquitin lysines, thus creating
a ubiquitin chain. A chain of at least four ubiquitins linked via lysine
48 is the classical recognition motif for proteasomal degradation [3],
though chains of other linkage types are now recognized as physiologi-
cal targeting motifs, and for some substrates multiple monoubiquitin
modiﬁcations are sufﬁcient for targeting to the proteasome [4,5]. The
proteasome holocomplex or 26S proteasome consists of two entities: a
central cylindrical structurewith peptide hydrolysis activity (core parti-
cle (CP) or 20S proteasome) and a regulatory particle (RP, also known as
the regulatory cap, 19S particle, or PA700), required for substrate recog-
nition, removal of the ubiquitin chain and ATP-dependent unfolding.
Medical interest in modulating proteasome function for therapeutic
purposes has signiﬁcantly increased during the past decade since the
ﬁrst proteasome inhibitor, Velcade/Bortezomib, has been approved
by the Food and Drug Association (FDA) in 2003 for the treatment of
refractory multiple myeloma [6]. Studies that led to the FDA approval
demonstrated that the proteasome can be transiently and safely
inhibited in humanswith anti-tumor activity especially against hemato-
poietic malignancies [6]. The efﬁcacy of proteasome inhibition for the
treatment of cancer is based on its role in regulating cell proliferation
and on the exquisite reliance of cancer cells on proteasome function
[7]. However, many diseases, especially neurodegenerative diseases
are characterized by the accumulation of toxic misfolded proteins and
eventual collapse of the proteostasis network. Thus, both proteasome
inhibition and activation represent potential avenues for future drug
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regulate the UPS have been unraveled. Mechanisms that speciﬁcally
modulate the proteolytic activity of the proteasome are discussed in
this review.
2. Major alternate forms of the proteasome
The central assembly of the proteasome is a cylindrical structure
that houses the proteolytic active sites. The cylinder is formed by two
different types of subunits, α and β, which are arranged in four stacked
heptameric rings enclosing a central cavity. In eukaryotes, seven distinct
α subunits are located in the two outer rings of the barrel, and seven dis-
tinct β subunits form the two inner rings [8]. Three of the β subunits
contain active sites with different peptide cleavage speciﬁcities. β1 has
a caspase-like speciﬁcity, cleaving after acidic residues; β2 is trypsin-
like, cleaving after basic residues; and β5 is chymotrypsin-like in
cleaving after large hydrophobic residues. Their active sites face the
interior of the cylinder. Access to the central cavity is regulated by an
adjustable gate that is formed by the N-terminal protrusions of the α
subunits [9,10]. The default status of the CP gate is closed and for
proteasomal degradation and substrate access the N-termini need to
be displaced from their axial position to reveal a continuous channel
leading into the catalytic cavity. Modulation of the gate is a prerequisite
for substrate entry into the proteolytic chamber and is mediated by
proteasome activators. Several proteasome activators have been de-
scribed, including the regulatory particle (RP/19S/PA700), activators of
the PA28 protein family and Blm10/PA200 activators [11]. All activators
share common binding sites on the two outer surfaces of the CP/20S
(Fig. 1). The binding pockets for activators are formedby interfaces of ad-
jacentα subunits. Themolecularmechanism of displacing theN-termini
of the α subunit, which results in gate opening, appears to be different
for the different activator families, and will be discussed below.PA200/Blm10
RP/19S/P
Fig. 1.Modular structure of proteasome complexes. The proteasome core particle can be cappe
themonomeric Blm10/PA200 proteins and the heptameric PA28/11S/REG rings (adapted from
site at the apical surface of the CP and open the CP gate.It should be noted that in the absence of activators the free CP shows
low but detectable activity towards small proteins with intrinsically
unstructured regions in the absence of ubiquitination and ATP [12].
The signiﬁcance of this activity is not understood but it may reﬂect the
occurrence of spontaneous, short-lived opening of the gate at some fre-
quency [13].
2.1. RP–CP: the proteasome holoenzyme
The dominant proteasome activator is the RP. It promotes ATP- and
ubiquitin-dependent substrate turnover. The RP can bind to either one
or two ends of the CP to form the proteasome holocomplex or 26S
proteasome. The RP is composed of 19 integral subunits, which form
two biochemically separable sub-complexes, lid and base [14]. The
base subcomplex is situated proximal to the CP gate region. It contains
six homologous ATPases (Rpt1–Rpt6), which form a hexameric ring.
They belong to the AAA family of ATPases. The ring is not planar
but has a spiral staircase-like topology, with Rpt3 at the highest and
Rpt2 at the lowest position [15–17]. In addition to the ATPases, the
base contains the two largest RP subunits, Rpn1 and Rpn2, and the
two ubiquitin-receptors Rpn10 and Rpn13 [18]. The lid consists of
nine non-ATPase subunits. One Rpn subunit, Rpn6, appears to contact
both the base as well as the α ring and might be a crucial regulator
of lid–base assembly [15,19]. One of the non-ATPases, Rpn11, has
deubiquitinating activity and is located in close proximity to the sub-
strate entry pore formed by the ATPase ring [15]. Its deubiquitinating
activity is required to promote the degradation of ubiquitinated
proteasome substrates [16,20–22].
Cryo-EM studies have deﬁned two conformational states of the RP,
ATP-h and ATP-γS. The ATP-h structure, the ﬁrst to be deﬁned [15,17]
is now seen as likely to represent a basal state of the enzyme. This struc-
ture is deﬁned by the presence of ATP in the buffer and the absence ofA700
PA28/11S/REG
d with three different activator complexes: the hetero-oligomeric RP/19S/PA700 particle,
[11] and [15] with permission). Activators from all three families occupy the same binding
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the designation ATP-h. However, the exact nucleotide state of ATP-h
proteasomes is uncertain, since the attainable resolution at present
does not allow for nucleotides to be visualized within the complex.
Most likely some combination of ATP andADP is present among the var-
ious ATPase sites of the complex.
ATP-γS proteasomes are deﬁned by the presence of the non-
hydrolyzable, or slowly hydrolyzed analog of ATP, ATP-γS. Major
rearrangements of the RP are involved in the transition between the
ATP-h and ATP-γS forms of the proteasome holoenzyme [17]. A com-
mon feature of these rearrangements is that they appear to poise the
RP in a conformation better suited to drive substrate degradation.
Because the proteasome may engage continuously in ATP hydrolysis,
it is possible that it is never bound only to ATP, but rather to a mixture
of ATP and ADP. This raises the possibility that the ATP-γS structure
might not represent a physiological state of the enzyme. This, however,
does not appear to be the case, since a similar form of the RP has been
deﬁned by trapping the RP in the presence of ATP and a ubiquitinated
substrate that cannot be hydrolyzed due to mutational inactivation of
Rpn11 [23]. Thus, the ATP-γS structuremay represent the conformation
of the proteasome as it is poised to degrade substrate. Among the signa-
ture features of the ATP-γS structure are (i) a movement of Rpn11 to-
wards the substrate entry port of the RP, where it presumably releases
ubiquitin from the substrate as the substrate is translocated into the
RP channel, (ii) awidening of the translocation channel, and (iii) a repo-
sitioning of the RP channel so that it is more closely aligned to that of
the CP [17,23].
Gate opening, and thus proteasome activation by the RP, is pro-
moted by the ATPase ring. Three of the ATPases, Rpt2, Rpt3, and Rpt5,
dock into cognate binding pockets within the CP α ring [15,16]. These
subunits contain a characteristic motif at their C-termini, a HbYX-
motif [24,25], characterized by a hydrophobic residue, a conserved
tyrosine at the penultimate position, and a variable C-terminal residue.
Previous studies indicate that hepta-peptides containing this motif are
able to activate latent isolated CP and thus are sufﬁcient to induce gate
opening [24,26]. Based on these observations and on structural informa-
tion obtained from a co-crystal structure with another HbYX-motif con-
taining proteasome activator Blm10 (see below) [27] the most likely
mechanism by which the HbYX-motif induces gate opening is through
a displacement of conserved residues in the binding pockets of the
α ring, which leads to long-range structural changes in the N-termini
of the α subunits, which constitute the gate. This displacement opens
a channel leading into the catalytic chamber. In several alternate
forms of the proteasome, the open state of the CP gate is stabilized by
interactions between the CP N-termini and elements within the axial
pore of the activator complex. This has been shown for two complexes
described in more detail below, PA28-CP [10] and Cdc48-CP [28].
These ﬁndings suggest that the open state of the CP N-terminimay sim-
ilarly be stabilized by interactionswith the residues lining the axial pore
of the Rpt ring in the proteasome holoenzyme.
Even though docking of the three HbYX motif-containing ATPases
opens the proteasome gate, the resulting entry port does not allow for
the passage of folded proteins. Prior to substrate entry, target proteins
need to be unfolded, and this activity is provided by the proteasomal
ATPases as the substrate is forced through the narrow translocation
channel in an ATP-hydrolysis-dependent fashion [29,30].
2.2. Blm10/PA200-CP
Blm10/PA200 proteasome activators are conserved from yeast to
humans and represent monomeric proteins of ~250 kDa. They form
hybrid complexes in which Blm10/PA200 binds to one end and the RP
to the opposite end of the CP cylinder [31,32]. Their cellular functions
are emerging. Blm10 binds to the proteasome during the late phases
of CP maturation and, like the RP, Blm10 contributes to the ﬁnal matu-
ration of CP complexes [33,34]. One physiological target for Blm10–proteasome complexes has been identiﬁed to date, the transcription
factor Sfp1, which regulates ribosomal protein genes [35]. Additional
studies suggest a potential role for Blm10 in the maintenance of mito-
chondrial homeostasis [26,27], a hypothesis that is supported by data
obtained from mice that lack PA200, the ortholog of yeast Blm10.
PA200−/− mice exhibit male fertility defects caused by impaired sper-
matogenesis [36], a process involving signiﬁcant mitochondrial and
metabolic changes. Further studies suggest a role for Blm10/PA200 acti-
vators in DNAor oxidative damage repair aswell as in chromosome sta-
bility [31,37,38] most likely through ATP- and ubiquitin-independent
degradation of acetylated histones in somatic cells [39]. Loss of PA200
inmice also leads to delayed core histone clearance in elongated sperma-
tids [39]. Considering the impaired spermatogenesis of PA200 knock-out
mice [36] these data suggest that PA200-mediated degradation of his-
tones might be an essential mechanism for correct sperm formation.
The tertiary structure of Blm10/PA200 proteins is characterized by
an array of HEAT repeats, which form an elongated solenoid [27]. The
repeats make extensive contacts with the α ring surface. A co-crystal
structure of reconstituted Blm10–CP complexes showed that Blm10
binding to the CP results in an at least partially open gate [27]. The con-
formations of the N-terminal residues of four of the α subunits are su-
perimposable with the open gate conformation of PA26–CP complexes
[40]. The remaining three N-termini could not be visualized, indicating
that they are also displaced from the closed gate conformation. Bio-
chemical and crystallographic data also revealed that Blm10–CP associ-
ation is mediated by the Blm10 C-terminus [26,27]. As observed for the
proteasomal ATPases, the C-terminus of Blm10 contains a HbYX-motif
[26], and a heptameric peptide derived from the Blm10 C-terminus is
sufﬁcient to activate latent CP [26]. The position of the penultimate tyro-
sine within the CP binding pocket suggests a gate opening mechanism
that is shared between theHbYXmotif-containing proteasomal ATPases
and Blm10.
Crucial for stabilizing the open gate conformation is the position of
the conserved residue Pro17 within the α pocket, as ﬁrst shown by
work on the structure of the PA26–CP complex [40]. The penultimate
tyrosine of Blm10 forms a hydrogen bond with the main chain oxygen
of Gly19, which leads to a displacement of Pro17 and subsequent long-
range alterations of the conformation of the α subunit N-termini. These
conformational changes in the α subunit N-termini stabilize the open
gate conformation. The structural changes within the proteasome gate
are sufﬁcient to allow passage of the small, unstructured proteasome
substrate tau-441 as demonstrated in vitro [26] and thus gate opening
promotes the degradation of certain proteins.
2.3. PA28–CP
The PA28/11S/REG proteasome activator family is expressed in
higher eukaryotes and some unicellular eukaryotes, notably trypano-
somes. In mammals, three different isoforms form two separate activa-
tors with different localization, induction and activation properties.
PA28α and PA28β are 28-kDa proteins, which form hetero-heptameric
rings in vertebrates [41,42]. They bind to the CP in the cytoplasm
or form hybrid complexes, where PA28 binds to one end of the CP
and the 19S/PA700 complex to the opposing end [43–45]. Both subunits
are inducible by interferon-γ, which suggested a potential role of
PA28αβ in MHC Class I mediated antigen presentation [46]. Indeed,
binding of PA28αβ affects the generation and presentation of a subset
of viral antigens [47]. Although induced by cytokines, PA28αβ is present
at a basal level in all tissues [48]. Thus, the cellular function of this class of
proteasome activators has perhaps not been fully elucidated yet. A third
PA28 isoform, PA28γ, forms homo-heptameric rings and is found in the
nuclei of vertebrates as well as invertebrates [41,42]. In mice, the loss of
PA28γ results in reduced body size, and embryonic ﬁbroblasts derived
from these mice exhibit cell cycle defects [49]. Consistent with these
ﬁndings, PA28γ promotes ATP- and ubiquitin-independent degradation
of speciﬁc small regulatory proteins such as p21 and SRC-3 [50,51].
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nism. As with the proteasomal ATPases, association with the CP is
mediated via docking of the PA28 subunits' C-termini into cognate
binding pockets within the α subunits [40]. In contrast to the three
proteasomal ATPases that dock into the CP surface, and Blm10, PA28
proteins lack the HbYX-motif. Thus, a direct structural change of the
gate is not promoted by insertion of the C-termini. Instead, PA28
proteins utilize an internal loop structure, the activation loop, which
contacts the 20S alpha subunits at Gly19 to stabilize Pro17 in a confor-
mation, which promotes opening of the gate [40]. Three of the six
proteasomal ATPases dock into the CP surface and the monomeric
Blm10/PA200 activators insert into one pocket. Thus, the gate can be
opened asymmetrically and without full occupancy of all seven binding
pockets. PA28 activators, on the other hand, insert all of their seven
C-termini.
2.4. Immunoproteasomes and thymoproteasomes
In addition to proteasome activators, higher eukaryotes also express
three alternate proteolytically active subunits, Lmp2, Lmp7 andMECL-1.
Lmp2 and Lmp7 were initially identiﬁed because these genes were lo-
calized in a genomic region that is responsive to cytokines. Sequence
analysis of Lmp2 and Lmp7 revealed homology to proteasome β sub-
units [52,53]. Their cytokine-inducible expression suggested a potential
role in the generation of antigenic peptides by the proteasome and they
were accordingly called immunosubunits. Later a third subunit with ho-
mology to active site subunits was identiﬁed, MECL-1. Its expression
is also sensitive to cytokines [54,55]. All three immunosubunits are
incorporated into the proteasome core to form immunoproteasomes
or i-proteasomes. Lmp2 replaces β1, and is thus termed β1i, whereas
Lmp7 replaces β5, and MECL-1 β2. The two latter immunosubunits
display essentially the same cleavage speciﬁcity as their housekeeping
counterparts. Lmp2 on the other hand provides a chymotrypsin-like
activity, in contrast to its constitutive counterpart, the caspase-like
β1. Thus, Lmp2 incorporation both attenuates the caspase-like activity
of constitutive proteasomes and ampliﬁes the chymotrypsin-like activ-
ity beyond that of β5 or β5i alone [56]. It was suggested that increased
generation of peptides with hydrophobic residues should improve
MHC Class I antigen presentation, since the preferred peptides for the
MHC Class I molecules are peptides with a hydrophobic C-terminal
residue. Despite this there were surprisingly modest effects on the
immune response in mice deleted for either one, two, or all three
immunosubunits as summarized in ref. [57]. Recent studies, however,
with i-proteasome deﬁcient mice and additional cell biological and
biochemical data suggest that the function of the i-proteasome might
go beyond antigen presentation. A role in the clearance of oxidatively
damaged proteins was proposed [58,59], especially during inﬂamma-
tion [59], in the regulation of tumor development, in lipid metabolism
[60] and in NFκB signaling [58]. Whether immunoproteasomes have
the capacity to alter the clearance of ubiquitinated proteins after inter-
feron-γ treatment, as has been proposed [59], is currently debated
[61].
The newest member of alternate proteolytic active subunits of
the proteasome has been identiﬁed during a homology search of the
human and the mouse genome. The identiﬁed gene is homologous to
β5 and is exclusively present in the thymus [62]. Incorporation ofβ5t re-
sults in a reduction of the chymotrypsin-like activity of the proteasome
[62]. Current studies point to a specialized role of β5t-containing
thymoproteasomes in the positive selection of CD8+ T cells [63].
3. Exchangeable and substoichiometric proteasome regulators
3.1. Ubiquitin receptors
Recognition of ubiquitinated target proteins by the proteasome
is achieved by two intrinsic ubiquitin receptors: Rpn10 and Rpn13[18,64]. In addition, several ubiquitin binding proteins serve as shuttle
factors, which deliver ubiquitinated substrates to the proteasome. The
shuttle factors contain both a ubiquitin binding domain (UBD) and a
ubiquitin-like domain (UBL). While the UBD promotes the binding of
ubiquitinated substrate proteins, theUBLdomain is required for interac-
tion of the shuttle factors with the UBDs of intrinsic ubiquitin receptors
or with Rpn1. The three known shuttle factors in yeast are Rad23 [65],
Dsk2 [66], and Ddi1 [67].
3.2. Deubiquitinating enzymes and ubiquitin ligases
Two conserved deubiquitinating enzymes (DUBs) interact revers-
ibly with the proteasome: Ubp6/Usp14 and UCH37/Uch2 [68,69].
Usp14 antagonizes the degradation of ubiquitinated substrates by the
proteasome [68,70], and likely Uch37 as well [69,71]. In contrast, the
DUB activity of the intrinsic proteasome subunit Rpn11 promotes deg-
radation. While inactivation of the deubiquitinating activity of Rpn11
prevented the degradation of proteasome substrates [20,21], deletion
of UBP6 results in enhanced proteasome activity [68]. These antago-
nistic effects of deubiquitination at the proteasome may reﬂect, at
least in part, the nature of the cleavage site preferences of these
DUBs. While Ubp6 and UCH37 are thought to remove ubiquitin pref-
erentially from the distal end of the chain [68,71], Rpn11 appears to
cut at the base of the chain, thus removing the chain en bloc. Rpn11
is located within the proteasome RP close to the ATPase ring
[15,16], so that active translocation of the substrate by the ATPases
should presumably present the chain to Rpn11, while at the same
time carrying it away from the distally located Ubp6/Usp14. Once
such translocation has initiated, the substrate is likely no longer de-
pendent on the ubiquitin chain for proteasome binding, and therefore
deubiquitination by Rpn11 does not suppress substrate degradation.
Ubp6 on the other hand associates with Rpn1 at the outer surface of
the proteasome [15,72]. Thus, the effect of chain removal by Ubp6/
Usp14 on proteasome-substrate afﬁnity cannot be compensated by the
interaction of substrate with the ATPases. Consequently, it is thought
that the action of UBp6/Usp14 can result in premature release of the
substrate from the proteasome.
The importance of DUB activity ﬁrst became evident from studies on
the cellular effects of loss of UBP6 in yeast. In the absence of Ubp6, cells
acquire pleiotropic sensitivity to stress, accompanied by ubiquitin deﬁ-
ciency [73]. These data suggest that if ubiquitin chains are not trimmed
from the distal endbyDUBs, a high fraction of ubiquitin escapes theDUB
activity of Rpn11 and is degraded along with the conjugated substrate,
resulting in depletion of the cellular ubiquitin pool.
The inhibitory function of Ubp6 on the degradation of proteasomal
substrates is antagonized by a HECT domain ligase, Hul5, which simi-
larly associates with the proteasome [74]. Loss of HUL5 results in re-
duced degradation of ubiquitinated proteasome substrates and the
data suggest that proteasome-associated Hul5 has an important role
in extending existing ubiquitin chains, the deﬁning characteristic of
E4 ligases [74]. Longer ubiquitin chains show increased afﬁnity for
the proteasome [3], suggesting a simple mechanism by which Hul5
facilitates proteasome-mediated substrate degradation. This hypothe-
sis is supported by a recent study, which demonstrated that Hul5's
activity is crucial during heat stress, particularly for low-solubility sub-
strates [75].
Several additional ubiquitin ligases have been found to interact with
both yeast and mammalian proteasomes, such as Ubr1 and Ufd4 [76],
RNF2 [77], SNEV [78], SCF and APC complexes [79,80] and Parkin [81].
In most cases, proteasome association is thought to enhance substrate
turnover by eliminating the need for a ubiquitinated protein to migrate
to the proteasome [82]. If the interval between ubiquitination and
proteasome binding is substantial, the ubiquitin chains could be re-
leased from the substrate by deubiquitinating enzymes. An exceptional
case among proteasome-associated ligases is Parkin, which appears to
modulate proteasome assembly [81].
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As described above, the HbYX motif found in three of the six
proteasomal ATPases, as well as in Blm10, mediates CP binding and
gate opening. HbYX-motifs have been identiﬁed in the C-termini of
other proteins as well. While the HbYX-motifs of the CP chaperones
Pba1–Pba2 promote binding to inactive, immature CP subcomplexes
and do not activate mature 20S [83], two other studies report on
a proteasome activation function for proteins containing this motif:
the Drosophila protein DmPI31, and Cdc48 isolated from the archaeon
Thermoplasma acidophilum. PI31 was previously described as a
proteasome inhibitor [84,85]. Recent studies, however, suggest alter-
nate functions for PI31. Overexpression of PI31 in mammalian cells
did not result in decreased proteasome activity and a role for PI31
speciﬁcally in immunoproteasome formation was proposed [86]. In
Drosophila, overexpression of DmPI31 increased proteasome activity
in vivo and rescued the adverse effects of proteasome inhibition [87].
In vitro studies with puriﬁed DmPI31 revealed that the protein activates
26S proteasomes but inhibits the CP. The ability of PI31 to stimulate
proteasome activity is regulated by the F box protein Nutcracker, a com-
ponent of the SCF E3 ligase complex inDrosophila. Nutcracker, however,
does not promote turnover but rather stabilizes PI31 [87].
Cdc48/p97 is a conserved hexameric ring-shaped AAA ATPase com-
plex whose function is intimately tied to the ubiquitin–proteasome sys-
tem. Its functional characteristics resemble those of the proteasomal
ATPases: ubiquitin binding and protein unfoldase activity mediated by
ATP-hydrolysis [88]. Cdc48 has been observed to remove ubiquitinated
proteins from insoluble structures and from membrane-bound states
[89]. Curiously, the Cdc48 C-terminus comprises a conserved HbYX-
motif. A recent study revealed that archeal Cdc48 can dock onto the
CP and can activate its peptidase activity [28]. The same activities have
been shown for murine Cdc48, which can collaborate with murine
CP [90]. Whereas Cdc48 has generally been envisaged as functioning
upstream of the proteasome, delivering ubiquitinated proteins to the
proteasome holoenzyme to be degraded, these studies [28,90] raise
the interesting possibility that Cdc48-CP can also function as an alterna-
tive form of the proteasome.
4. Transcriptional regulation of the proteasome
4.1. Rpn4
Proteasomes are abundant cellular constituents. However, under
proteotoxic stress the basal level of proteasomes can become limiting
for cell survival. To adapt proteasome levels to the cellular need for
removal of damaged proteins, eukaryotic cells respond through tran-
scriptional upregulation of proteasomal genes. This process involves
coordinate upregulation of all proteasome genes, and is conserved
across species [91,92]. In S. cerevisiae the mechanisms that regulate
proteasome expression arewell understood. A single transcription factor,
Rpn4, which binds to Proteasome Associated Control Elements (PACE)
present in the promoter of all proteasome genes [93,94], is required for
the adaptive expression of proteasomal subunits (though not all Rpn4
target genes encode proteasome components) [95]. Rpn4 is a C2H2-
type zincﬁnger-containing transcription factor. The transcriptional activ-
ity of Rpn4 is regulated by a negative feedback loop [96] (Fig. 2). Under
normal growth conditions Rpn4 has a very short half-life of ~2 min and
is degraded by the proteasome via ubiquitin-dependent and ubiquitin-
independent pathways [97]. Ubiquitin-dependent degradation of Rpn4
is mediated by the E3 ligase Ubr2 [98]. Additional regulation of Rpn4
abundance is achieved via transcriptional control of the RPN4 gene.
Binding sites for Hsf1, the major regulator of proteins involved in allevi-
ating heat stress, for Yap1, a transcription factor involved in upregulating
detoxifying enzymes during oxidative stress, and for Pdr1 and Pdr3,
which mediate pleiotropic drug resistance, are all present in the pro-
moter of RPN4 [99]. Activation of RPN4 transcription by these stress-inducible transcription factors ensures that diverse proteotoxic stresses
result in upregulation of proteasome levels.
4.2. Nrf1/Nrf2/SKN-1
In mammals, short-term treatment of cells with proteasome inhibi-
tors results in the upregulation of proteasomal genes. Two studies
link the nuclear factor erythroid derived 2-related factors 1 (Nrf1)
to the regulation of this response [100,101], while other ﬁndings impli-
cate Nrf2 in the stress-responsive regulation of proteasomal genes
[102–105]. Both transcription factors belong to the Cap‘n’Collar (CNC)
transcription factor family, characterized by a unique basic leucine zip-
per domain. Nrf1 and Nrf2 regulate a large number of genes involved in
antioxidant and xenobiotic defense [106]. A commonpromoter element
in genes recognized by Nrf1 and Nrf2 is the antioxidant response
element (ARE) [107]. They are therefore thought to have overlapping
transcriptional activity, although differing strongly in their regulatory
mechanisms, cellular localization, and in the phenotypes of the respec-
tive knockout mice. Nrf1 is an integral membrane protein of the
endoplasmic reticulum (ER) [108], while Nrf2 is localizedwithin the cy-
toplasm and atmitochondria under non-inducing conditions [109]. Nrf1
ablation in mice results in developmental defects and lethality caused
by impaired liver erythropoiesis [110], while Nrf2−/− mice develop
normally but are highly sensitive to oxidative stress. Nrf2−/−mice also
develop neurodegenerative disorders, cancer, and autoimmune disease
[111,112]. Both Nrf proteins are regulated at the protein level via
proteasome-mediated degradation. The ligases SCFβTrCP and Hrd1 have
been found to be required for Nrf1 turnover [113]whereas a Cul3 family
ligase that uses the KEAP protein for substrate recognition is required
for regulated Nrf2 turnover [101,114]. Although adaptive proteasome
gene upregulation involves Nrf1 or Nrf2 activity, it is unclear yet wheth-
er these factors bind directly to proteasomal gene promoters. Putative
AREs have been identiﬁed in proteasomal genes [100,101], however,
direct recruitment has not been shown, and a transcriptional analysis
of liver-directed ablation of Nrf1 in mice did not alter the transcript
levels of proteasomal genes [107].
Similarly to the response of mammalian cells to proteasome inhibi-
tion, reduced expression of proteasome genes in C. elegans activates
SKN-1, the worm ortholog of Nrf1 and Nrf2 [115], and short-term
proteasome inhibition leads to a compensatory upregulation of
proteasomal genes via SKN-1 [116]. SKN-1 dependent upregulation
of proteasomal genes is also observed upon treatment of C. elegans
with H2O2 [117]. Furthermore, as described for Nrf2, SKN-1 levels are
regulated by a cullin E3 ligase [118]. Interestingly, chromatin-IP (CHIP)
experiments revealed that SKN-1 was bound to most proteasomal
gene promoters during the L1 larval stage [119]. Recent studies suggest
that the role of SKN-1 in regulating proteasome gene expression in re-
sponse to proteotoxic stress is tissue speciﬁc and is coupled to the regu-
lation of factors required for correct protein translation [116].
In summary, the data discussed provide compelling evidence that
CNC transcription factors might be involved in the adaptive transcrip-
tional regulation of proteasome genes. Furthermore, negative feedback
regulation as described for Rpn4 in yeast appears to be conserved as
well in higher eukaryotes (Fig. 2).
4.3. FoxO/DAF-16
Recent evidence suggests that the role of SKN-1 in the regulation of
proteasomal genes might depend on the reproductive state in worms.
In germline-ablated (glp-1[e2141]) mutants, proteasomal gene tran-
scription was independent of SKN-1. The mutants exhibited elevated
proteasome levels, which were lost upon knocking down the FoxO
transcription factor DAF-16 but not SKN-1 [120]. While previous
studies demonstrated that FoxO transcription factors are regulated
by proteasome-mediated degradation [121] the effect of DAF-16 on
proteasome expression in germ line deleted worms represents the
PACE/ARE gene transcription on
TF
E3
PACE/ARE gene transcription off
TF
E3
TF
A
B
Fig. 2.Model for feedback regulation of proteasomal gene transcription. A)Under normal growth conditions proteasomes are expressed at basal levels. Elevated expression of proteasomal
genes is prevented via rapid ubiquitin-dependent degradation of a transcription factor (TF) that recognizes speciﬁcmotifs in the promoter of proteasomegenes: PACE and ARE elements in
yeast and mammalian cells, respectively. B) Proteotoxic stress (indicated by accumulating damaged proteins symbolized as stars) saturates existing proteasome complexes, resulting in
stabilization of the transcription factor and subsequent increased expression of proteasomal genes.
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proteasomal function. In contrast to Nrf1/2/SKN-1, which appear to be
involved in the regulation of all proteasomal genes, however, only one
proteasome subunit was found to be up-regulated in glp-1(e2141)mu-
tants, RPN-6. Proteasome levels, however, remained unchanged. The
authors argue that due to the speciﬁc topology of Rpn6 within the 26S
proteasome, the positioning of which suggests a role in helping to
bridge the RP and CP [15,19], elevated RPN-6 levels might have a posi-
tive effect on the overall activity of the proteasome [120].
FoxO also induces increased proteolysis in atrophic muscles. While
the major target for FoxO during muscle atrophy is the lysosomal
arm of cellular proteolysis, it also activates certain E3 ligases, termed
atrogenes and thus stimulates proteasomal degradation of muscle pro-
teins [95,122].
5. Post-translational modiﬁcations of the proteasome
Large-scale studies to deﬁne the phospho-proteome aswell as other
post-translational modiﬁcations both in yeast [123] and in higher
eukaryotes [124] revealed that almost all proteasome subunits as well
as the activators PA28 and Blm10 are phosphorylated. In addition,
acetylation, myristoylation, ubiquitination, modiﬁcation with O-linked
N-acetyl-glucosamine (O-GlcNAc), S-glutathionylation and oxidation
of proteasome subunits have been detected. Accumulating evidencesuggests that these modiﬁcations might modulate proteasome activity.
O-GlcNAc and oxidation results in proteasome inactivation [125–128].
Myristoylation of Rpt2 affects the localization of the proteasome
[129]. Mono-ubiquitination of Rpn10 regulates substrate recruitment
and interaction with proteasome shuttle factors [130,131]. Reversible
S-glutathionylation of cysteines in CPα subunits were found to activate
isolated CP, an effect that was caused by gate opening [132]. Nuclear
mammalian CP was also found to be poly-ADP ribosylated. This modiﬁ-
cation enhanced the activity of the CP towards ﬂuorogenic peptides and
oxidized histones [133] and ADP-ribosylation of PI31 regulates its inter-
action with the proteasome and affects proteasome assembly [134].
Several reports document both activating and inactivating functions
for the phosphorylation of proteasome subunits, depending on the
kinase. In vitro and in vivo studies propose a positive effect of protein
kinase A (PKA) activity on proteasomal function [135–137]. PKA also
inﬂuences proteasome assembly [138]. In neurons phosphorylation
of Rpt6 by Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα)
results in increased proteasome activity and function [139]. Rpt6 phos-
phorylation has also been implicated in regulating proteasome assem-
bly [140].
An inhibitory role for proteasome phosphorylationwas proposed by
a study that found the kinases c-Abl and Arg tyrosine kinase to interact
with the proteasome and to phosphorylateα4, which led to a reduction
in proteasome activity [141]. Similarly, phosphorylation of Rpn2 by p38
19M. Schmidt, D. Finley / Biochimica et Biophysica Acta 1843 (2014) 13–25MAPK inhibited the activity of 26S proteasomes during osmotic stress
[142]. Opposing effects of proteasome phosphorylation are also evident
from studies focused on protein phosphatases. Phosphatase PP2A was
reported to activate proteasome activity [143], whereas phosphatase
UBLCP1, which contains a UBL domain, is recruited to the proteasome
and inhibits proteasome assembly as well as its catalytic activity [144].
In summary, the post-translational modiﬁcations of the proteasome
and their effects on its assembly, localization, and function are complex
and provide a signiﬁcantly increased layer of complexity to known
proteasome regulatorymechanisms, whichmight ﬁne tune proteasome
function to speciﬁc cellular environments and cellular demands.
6. The proteasome as a therapeutic target
6.1. Cancer
Over the last decade, the potential applications of proteasome inhi-
bition in disease have been explored extensively. Due to its broad im-
pact on cellular functions, the proteasome was initially not considered
to be a good target for the development of clinical drugs. Indeed,
proteasome inhibition, if severe, disrupts the cell cycle and cellular pro-
tein homeostasis. Cells also activate cell death programs and apoptosis
in response to prolonged proteasome inhibition. However, early studies
demonstrated that certain types of cancers are exquisitely sensitive to
proteasome inhibition [145,146]. Subsequent work revealed that nu-
merous cancer types exhibit an aberrant function of the UPS [7,147]
and thus treatmentwith proteasome inhibitorsmight prove to be a suc-
cessful strategy.
Initial studies with the peptide boronate proteasome inhibitor PS-
341 (nowcalled velcade or bortezomib) showed that the drug exhibited
clinical activity especially towards hematologic malignancies [148,149].
Bortezomib is a reversible inhibitor, which preferentially blocks the
chymotryptic activity of the proteasome [150]. In 2003 bortezomib
was approved by the US Food and Drug Administration (FDA) for the
treatment of refractory multiple myeloma. It also exhibits efﬁcacy in
non-small cell lung cancer, mantle cell lymphomas and pancreatic can-
cer [151]. Bortezomib treatment, however, leads to the development of
resistance. Adverse side effects include peripheral neuropathy, gastroin-
testinal problems, thrombocytopenia, asthenia, cardiac and pulmonary
disorders and pain [151]. Thus, the development of new UPS-related
drugs with reduced toxicity is desirable.
Several second-generation proteasome inhibitors are currently in
clinical trials both for the treatment of hematologic malignancies
and for solid tumors. Most of these newly developed inhibitors also in-
hibit the chymotrypsin-like activity of the proteasome, like bortezomib,
but show increased chemical stability, different binding afﬁnities for the
proteasome as well as altered toxicities in the clinic [150]. Accelerated
approval by the FDAwas granted to theproteasome inhibitor carﬁlzomib
in 2012 for the treatment of patients with multiple myeloma, which
failed to respond to prior therapies. Carﬁlzomib has shown efﬁcacy in
bortezomib-resistant multiple myeloma patients [152]. In contrast to
bortezomib, carﬁlzomib is an irreversible peptide epoxyketone inhibitor
[152]. For a detailed description of current research on proteasome in-
hibitors see ref. [150].
6.2. Immune-related diseases
At the organismal level, proteasome inhibition results in decreased
inﬂammatory and immune responses, with cell migration and cell
adhesion being compromised [151]. The effects of proteasome inhibi-
tion on the immune system owe in part to the fundamental role of
the proteasome in antigen presentation. A commonly observed toxicity
during clinical administration of bortezomib is lymphopenia [149], thus
bortezomib apparently has suppressive or toxic effects on the T-cell
compartment. Subsequent studies showed that proteasome inhibition
leads to T-cell apoptosis [153]. Activated T-cells are more susceptibleto proteasome inhibition than resting T-cells [154], suggesting that
proteasome inhibition might be a successful strategy to treat diseases
involving activated T-cells, such as graft-versus-host disease (GVHD).
Proteasome inhibition also results in depletion of alloreactive T-cells,
whereas the immune defense against pathogens remains intact [154],
suggesting that proteasome inhibition might be a viable strategy for
the treatment of autoimmune diseases. These hypotheses are under in-
vestigation with several successful preclinical studies in mouse models
for autoimmune encepahlomyelitis, GVHD, arthritis, colitis, systemic
lupus erythematosus, myastenia gravis and allograft rejection [155].
Alternate forms of the three proteolytically active β subunits are
incorporated into the proteasome CP in response to cytokines to gener-
ate the immunoproteasome (i-proteasomes). Recently the crystal struc-
ture of the i-proteasome has been solved [56], demonstrating that
the active site architecture of the inducible subunits differs from that
of the constitutive counterparts. This has allowed the synthesis of
immunoproteasome speciﬁc inhibitors. Since i-proteasomes represent
a minor fraction of the proteasome population and are found predomi-
nantly in cells involved in the immune response, it is expected that
treatingpatientswith inhibitors that speciﬁcally inhibit the i-β subunits,
but not the constitutive proteasomes, should result in reduced toxicity
[150]. In initial studies utilizing these novel proteasome inhibitors, they
were found to inhibit the growth of multiple myeloma cell lines and ex-
hibit anti-inﬂammatory and immunosuppressive effects [156,157].
6.3. Neurodegenerative diseases
A unifying characteristic of neurodegenerative diseases is the depo-
sition of aggregated, misfolded proteins. This is true of Alzheimer's
disease (AD), Parkinson's disease (PD), Huntington's disease (HD),
Amyotrophic lateral sclerosis (ALS) and spongiform encephalopathies.
Aggregation can occur in the cytoplasm, the nucleus or in the extracel-
lular space. If unchecked, the accumulation of misfolded protein can
disrupt cell and tissue function. Protein aggregation in general may be
an indication of a compromised proteostasis network. Therefore, a
wide body of research has assessed the role of the UPS in these diseases.
This review will focus on the involvement of the proteasome in neuro-
degenerative diseases. The effect of the ubiquitination machinery has
been discussed in detail previously [158].
Alzheimer's disease is the most prevalent neurodegenerative disease.
It is estimated that ~30% of the human population over 85 years old
show pathological signs of AD [159]. AD is characterized by progressive
loss of cognitive function and dementia, resulting in memory loss,
personality changes, psychosis, and language disturbances. Theprogres-
sive intellectual decline in AD patients is accompanied by an increase in
the deposition of protein aggregates that eventually form intracellular
neuroﬁbrillar tangles (NFT) and extracellular senile/amyloid plaques
[160]. The major component of NFTs is hyperphosphorylated tau,
while senile/amyloid plaques containmostly amyloid-β (Aβ). The latter
is produced via endoproteolytic cleavage of the membrane-associated
amyloid precursor protein (APP). Aβ aggregates in the extracellular
space after incorrect cleavage of APP by processing proteases, the
secretases [161]. While not directly participating in the generation
of Aβ or the elimination of extracellular Aβ, the UPS may, according
to previous reports, be involved in the degradation of APP via the
endoplasmic reticulum-associated degradation (ERAD) arm of the
UPS [162] and intracellular Aβ aggregates appear to inhibit the UPS
[163].
The second protein associated with Alzheimer's disease, tau, is a
structural protein, which associates with microtubules and has a role
in axonal transport [164]. Tau is an intrinsically unstructured protein
and in vitro degradation experimentswith puriﬁed components showed
that tau canbedegraded by theCPwithout prior ubiquitination [26,165].
ATP-dependent unfolding by the RP is also not required for in vitro
proteasome-mediated degradation of tau. However the relevance of
these observations to tau degradation within cells is not established.
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to suppress this potential pathway of degradation. Proteasome activator
Blm10 can also accelerate in vitro tau degradation [26]. Whether PA200,
the human counterpart of Blm10, plays a similar role in tau degradation
remains to be established.
Studies of tau turnover within cells point to roles for both autophagy
and the UPS. There is little consensus on the relative importance of
these pathways, possibly reﬂecting that, in the case of tau, the balance
between autophagy and the proteasome will depend on cell type, tau
overexpression, and similar experimental variables. Moreover, distinct
pools of tau may be degraded differently. For example, hypoacetylated
tau is a preferred substrate of the UPS [166,167]. Also, when tau is
not bound to microtubules it readily associates with Hsp70, where it
may encounter the ubiquitin ligase CHIP, which can ubiquitinate tau
and target it to the proteasome [168,169]. Tau degradation can also be
promoted when deubiquitination by the proteasome-associated
deubiquitinating enzyme Usp14 is inhibited [166]. The dependence of
tau degradation on CHIP and Usp14 indicates that in cells tau degrada-
tion by the proteasome is ubiquitin-dependent, although whether it is
fully ubiquitin-dependent remains to be clariﬁed. See reference [166]
for a comprehensive discussion of the literature of tau degradation.
Co-immunoprecipitation experiments revealed that ﬁbrillar tau co-
precipitated with the proteasome, and proteasome activity was signiﬁ-
cantly reduced in AD patients, as compared to age-matched controls
[170]. These data suggest that aggregated taumight inhibit proteasomal
activity, which, due to the pleiotropic effects of proteasome function
within cells, could contribute to the pathology of AD.
Parkinson's disease is a prevalent age-related neurodegenerative dis-
order affecting ~3% of the human population over 65 years. The typical
symptoms of PD are rigidity, shaking and slowness of movement. The
characteristic pathology found in PD patients involves Lewy Bodies in
dopaminergic neurons in the substantia nigra of the brain. The major
components of Lewy Bodies are α-synuclein, chaperones, ubiquitin,
the E3 ligase parkin, and other proteins involved in the UPS. As tau,
α-synuclein monomers are unfolded [171] and can be degraded by
the 20S core particle without prior ubiquitination and in the absence
of the RP [172]. Other studies, however, showed that depletion of the
proteasome subunit Rpt2 results in accumulation of α-synuclein and
the development of Lewy Body-like inclusions in mice, suggesting a
role for the RP in α-synuclein degradation [173,174]. This hypothesis
is supported by a recent study of German PD patients, which found
that variations in the gene PSMC4/Rpt3 correlated with the age of PD
onset [175].
Huntington's disease is the best-studied example of a group of disor-
ders, called polyglutamine (polyQ) diseases. Other diseases with the
same pathological mechanism are spinocerebrellar ataxia and spinal
and bulbularmuscular atrophy [176]. HD is an autosomal dominant dis-
ease, which is characterized by motor dysfunction, cognitive decline
and psychosis. The disease is caused by an expansion of a CAG triplet
repeat region in the huntingtin (Htt) gene through out-of-register re-
combination between repeat elements, leading to an expansion of a
poly-glutamine stretch in the N-terminal domain of Htt [177]. The Htt
proteins of healthy individuals contain 6–35 glutamines, whereas a
poly-glutamine stretch of N40 triggers the development of HD patholo-
gy [178]. Furthermore, disease progression correlates with the length of
the polyQ expansion. At the structural level, expansion of glutamine
stretches with more than 40 glutamines results in ﬁbril formation and
aggregation [179]. Aggregatedmutant Htt is found in intracellular inclu-
sion bodies in neurons. Although wild-type Htt has been associated
with a variety of cellular functions such as transcriptional regulation
and axonal transport, HD is most likely not caused by Htt loss of func-
tion, but rather by a toxic gain of function of the aggregated mutant
form. This hypothesis is supported by the ﬁnding that expression of
polyQ peptides in mice caused HD-like symptoms [180].
As in AD and PD, inclusions formed by mutant Htt contain both
ubiquitinated proteins and proteasome subunits. Aggregated Htt itselfwas found to be ubiquitinated [181]. In contrast, soluble mutant
Htt showed little cross reactivity with anti-ubiquitin antibodies [182].
Proteasome activity was reduced in brains derived from HD patients
and in mice models, but the origin of proteasome dysfunction remains
debated. Interestingly, while the chymotrypsin-like and the caspase-
like activity were reduced, the trypsin-like activity was markedly en-
hanced in post-mortem HD brains and in a mouse knock-in model
with Htt111Q [183]. The trypsin-like activity is required for the cleavage
after positively charged amino acids but also after glutamine and aspar-
agine. Apparently the upregulation of trypsin-like activity is unable to
compensate for the overall loss of proteasome activity as ubiquitinated
reporter proteins accumulate upon expression and aggregation of mu-
tant Htt [184].
Several models for impaired proteasome function in HD have been
proposed. Proteasomeswere found sequestered in Htt inclusion bodies,
which could explain the overall reduction in UPS function [185]. One
in vitro study suggested that the proteasomemight not be able to cleave
within polyQ stretches and that the released polyQ stretch would clog
the CP [186], while a second in vitro study was not in agreement
[187]. A subsequent, carefully designed study found that Htt aggregates
do not impair the general capacity of the proteasome to degrade
ubiquitinated substrates [182]. The authors concluded that proteasome
dysfunction might not originate from an inhibitory effect of the mutant
Htt oligomers on the proteolytic capacity of the proteasome, but rather
from a general proteostasis collapse.Whatever the cause of proteasome
dysfunction, enhancement of proteasome activity may be beneﬁcial in
cells challenged by polyQ-Htt, since upregulation of PA28γ transcrip-
tion improved cell survival in a cellular HD model [188].
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenera-
tive disorder affecting motor neurons. Familial ALS has been linked
to mutations in numerous genes [189]. Ubiquitinated inclusions are
found within motor-neurons in both familial and sporadic forms of the
disease, suggesting possible dysfunction of the ubiquitin–proteasome
pathway in ALS, whether in a causative role or otherwise. Interestingly,
mice with a conditional knockout of proteasome subunit Rpt3 in motor
neurons exhibited ALS-like pathology, particularly the accumulation of
protein aggregates with signature components of ALS inclusions, such
as the TDP-43 and FUS proteins [190]. These ﬁndings suggest that al-
tered turnover of proteasome substrates may play a signiﬁcant role in
the pathogenesis of ALS. A parallel experiment in which autophagy
was eliminated in motor neurons showed no such phenotypic effects
[190], arguing for the speciﬁcity of the results and for a distinct impor-
tance of the proteasome in motor neurons.
There is currently no effective treatment available that could cure or
substantially delay the progression of the neurodegenerative diseases
described above. These diseases are however, generally thought to be
characterized by decreased activity of the UPS. Therefore, drug develop-
ment strategies resulting in an increase of the proteolytic capacity of
the proteasomemight be beneﬁcial for disease progression. One speciﬁc
approach to this involves small-molecule inhibitors of Usp14 activity
[70]. Alternatively, one may envisage upregulation of proteasomal
gene expression, upregulation of proteasomal activators such as PA28
or PA200 or the identiﬁcation of small molecules that can activate the
CP by inducing gate opening.
6.4. Cardiomyopathies
Similar to neurological toxicity and altered immune response, treat-
ment of patients with bortezomib also led to an unexpected increase in
cardiac dysfunction such as arrythmia or congestive heart failure [191].
These observations are supported by reports, which demonstrate that
the UPS plays a major role in cardiac physiology and disease. Cardiac
diseases, especially hypertrophic and dilated cardiomyopathies as well
as ischemic heart diseases, are characterized by increased oxidative
damage to proteins, elevated levels of ubiquitinated proteins and
proteasome dysfunction [192]. A reduction of proteasome function is
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jury [126]. Short term and low level local treatment with proteasome
inhibitors led to controversial results. Both beneﬁcial and detrimental
outcomes have been reported (reviewed in [192]).
In a recent study, a causal link between proteasome dysfunction and
the progression of myocardial I/R injury has been established. The
authors created a transgenicmouse line in which a catalytically inactive
β5 subunit (β5T1A) was expressed in the heart at low levels. Under
normal conditions therewere no cardiac changes observed in the trans-
genic animals. However upon I/R injury increased cardiac damage was
observed [193]. Interestingly, the same animal model was used to
test the hypothesis that increased proteasome activitymight ameliorate
I/R injury. To that end the authors created a transgenic mouse line,
which overexpressed the proteasome activator subunit PA28α in the
heart and found that increased proteasome activity protected the
animals against I/R injury [194]. In a mouse model for desmin-related
cardiomyopathy (DRC) cardiac-restricted overexpression of PA28α also
reduced cardiac hypertrophy and extended the lifespan of the animals
[194]. These studies indicate a signiﬁcant involvement of proteasome
activity in cardiac function during I/R injury and in DRC.
6.5. Aging
A hallmark of aging is the progressive accumulation of damaged
macromolecules and a progressive decline in the function of the cellular
proteostasis network. A critical component of the proteostasis network
in aging cells is the proteasome. Many reports describe a decline in
proteasome function in aging cells, tissues and organisms (reviewed
in [195]). Age-related proteasome dysfunction occurs at many levels,
involving reduced expression of proteasome subunits [196], oxidative
damage resulting in reduced proteolytic activity [126,128], and dissoci-
ation of the holocomplex [128,197,198]. One view is that aggregated
proteins might form nonproductive complexes with the proteasome
and thus reduce its activity [199]. The importance of maintaining
proteasome function in aging organisms is highlighted by a recent
transgenic mouse model for proteasome dysfunction. In this model
the housekeeping β5 subunit was replaced with β5t, a thymus-
speciﬁc variant. As described above, proteasomes with incorporated
β5t have reduced chymotrypsin-like activity. The transgenic mice
exhibited signs of premature aging and had a signiﬁcantly shorter
lifespan [200].
Interestingly, several studies with exceptionally long-lived humans
(centenarians) and animals reported increased proteasome activity.
Proteasome expression and activity in ﬁbroblasts derived from healthy
centenarians were compared to ﬁbroblasts from young and old control
donors. Proteasome functionality in ﬁbroblasts derived from centenar-
ians resembled that of young donors [201]. Increased proteasome
capacity was also observed in the exceptionally long-lived naked mole
rat [202], a long-lived bat species [203], and in the giant clam, an excep-
tionally long-lived invertebrate [204].
The data above suggest that sustained proteasome activity might
correlate with the lifespan of an organism. This hypothesis has found
support through genetic approaches in several model organisms.
Overexpressing of the proteasome chaperone Ump1 led to increased
survival of yeast cells in stationary phase [205], a model for post-
mitotic aging. Overexpression of β5 in primary human embryonic ﬁbro-
blasts or of Rpn11 in Drosophila [206] extended lifespan. The latter re-
ports suggest that increased expression of a single proteasome subunit
can promote proteasome assembly, perhaps reﬂecting that these sub-
units are limiting for assembly in wild-type cells. A recent study utilized
information on transcriptional regulation of the UPS to elevate the
proteasome constitutively by stabilizing a transcription factor that reg-
ulates the adaptive increase in proteasome expression in response to
proteotoxic stress. In yeast, deletion of UBR2, the E3 ligase, which con-
trols the levels of Rpn4, leads to constitutive upregulation of the UPS,
enhanced proteasome capacity and a 70% increase in replicative lifespan[207]. These data suggest that enhanced proteasomeactivitymight slow
aging.
There are some common features of these studies that are worth
noting. First, it does not as yet seem that any one method of enhancing
proteasome function is unique in its ability to provide for enhanced
stress resistance and lifespan. Secondly, enhanced proteasome activity
has at least to date not been linked to detrimental effects on cell survival
and regulation.
7. Perspectives
As the ﬁeld of ubiquitination developed, the proteasomewas seen as
neither selective in its activity, nor rate limiting for degradation, nor
subject to signiﬁcant regulation. Prevailing views on these topics have
changed radically, as proteasome levels and activity have over the past
ten years been shown to be subject to ﬁne control via a vast array of
mechanisms, as described above. The existence of these mechanisms
may be taken as a sign that the output of the proteasome is a central
control point for protein degradation. The nature of these mechanisms
also indicates that cellular regulation and survival can tolerate adjust-
ments in proteasome activity, despite its importance in many aspects
of cell function. These considerations have been highlighted especially
by the success of proteasome inhibitors as anticancer agents.
Despite the clinical utility of proteasome inhibitors, one may
imagine that enhancing proteasome activity could also have therapeutic
beneﬁts in the proper context. Tens of diseases, many of them major,
are caused by toxic and often mutated proteins, the effects of
which could be neutralized if their levels could be reduced through
enhancing proteasome activity. Imbalanced protein homeostasis is
common among neurodegenerative diseases and cardiomyopathies,
and proteostasis collapse also is evident in aging cells. These diseases
are frequently characterized by increased damage to the cellular protein
pool, intracellular protein aggregation, and reduced proteasome activi-
ty. An attractive hypothesis for potential treatment of these diseases
is to upregulate components of the proteostasis network. In the last
few years increasing efforts have begun to test whether proteasome
up-regulation might be a viable approach for alleviating these diseases
and the published studies in different disease models and organisms
are encouraging.
A number of distinct strategies may be taken to enhance
proteasome activity. Among the most appealing is to inactivate endog-
enous proteins that serve to suppress proteasome activity. Since
ubiquitin targets substrates to the proteasome, deubiquitinating
enzymes are natural antagonists of the proteasome. In particular,
deubiquitinating enzymes Uch37 and Usp14, being physically associat-
ed with the proteasome, may suppress proteasome activity through
deubiquitinating a subset of ubiquitinated substrates, once the substrate
is docked at the proteasome. Speciﬁc, small molecule mediated inhibi-
tion of proteasomal deubiquitinating enzyme Usp14 has been reported
[70]. Proteasomes are also under negative control by the gate element
of the CP, which is regulated by proteasome activators. Any compound
or strategy that promotes the open state of this structure may stimulate
the degradation of either canonical, ubiquitin-dependent proteasome
substrates or noncanonical, ubiquitin-independent substrates. In gener-
al this approach may allow for substrates to bypass the proteasome ho-
loenzyme,with differential activation of the free form of the CP,which is
normally held under tight negative control. Direct activation of the CP
would be predicted to favor the degradation of unfolded substrates of
the proteasome. A ﬁnal possible approach to stimulate proteasome ac-
tivity is to increase its level via transcriptional up-regulation. It remains
unclear however, whether transcriptional circuitry that is dedicated
speciﬁcally to the proteasome exists in humans. In summary, these var-
ious approaches to proteasome modulation will be distinguished in
their relative feasibility and in the speciﬁcity of the effects that they
achieve. Although our understanding of physiological proteasome regu-
lation and of the potential therapeutic opportunities in up-regulating
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few years should provide exciting new information and a sharper vision
of the implications of proteasome modulation for the treatment of
human disease.
Acknowledgements
This work was supported by NIH grants RO1 GM084228 to M.S and
R37 GM43601 and R01 GM65592 to D.F.
References
[1] S.L. Lindquist, J.W.Kelly, Chemical and biological approaches for adapting proteostasis
to ameliorate protein misfolding and aggregation diseases: progress and prognosis,
Cold Spring Harb. Perspect. Biol. 3 (2011).
[2] D. Finley, Recognition and processing of ubiquitin–protein conjugates by the
proteasome, Annu. Rev. Biochem. 78 (2009) 477–513.
[3] J.S. Thrower, L. Hoffman,M. Rechsteiner, C.M. Pickart, Recognitionof thepolyubiquitin
proteolytic signal, EMBO J. 19 (2000) 94–102.
[4] N.V. Dimova, N.A. Hathaway, B.H. Lee, D.S. Kirkpatrick, M.L. Berkowitz, S.P. Gygi, D.
Finley, R.W. King, APC/C-mediated multiple monoubiquitylation provides an alter-
native degradation signal for cyclin B1, Nat. Cell Biol. 14 (2012) 168–176.
[5] N. Shabek, Y. Herman-Bachinsky, S. Buchsbaum, O. Lewinson, M. Haj-Yahya, M.
Hejjaoui, H.A. Lashuel, T. Sommer, A. Brik, A. Ciechanover, The size of the proteasomal
substrate determines whether its degradation will be mediated by mono- or
polyubiquitylation, Mol. Cell 48 (2012) 87–97.
[6] D.L. Esseltine, G. Mulligan, An historic perspective of proteasome inhibition, Semin.
Hematol. 49 (2012) 196–206.
[7] D. Hoeller, I. Dikic, Targeting the ubiquitin system in cancer therapy, Nature 458
(2009) 438–444.
[8] M. Groll, L. Ditzel, J. Lowe, D. Stock, M. Bochtler, H.D. Bartunik, R. Huber, Structure
of 20S proteasome from yeast at 2.4 Ǻ resolution, Nature 386 (1997) 463–471.
[9] M. Groll, M. Bajorek, A. Kohler, L. Moroder, D.M. Rubin, R. Huber, M.H. Glickman, D.
Finley, A gated channel into the proteasome core particle, Nat. Struct. Biol. 7 (2000)
1062–1067.
[10] F.G.Whitby, E.I. Masters, L. Kramer, J.R. Knowlton, Y. Yao, C.C.Wang, C.P. Hill, Struc-
tural basis for the activation of 20S proteasomes by 11S regulators, Nature 408
(2000) 115–120.
[11] B.M. Stadtmueller, C.P. Hill, Proteasome activators, Mol. Cell 41 (2011) 8–19.
[12] J.M. Baugh, E.G. Viktorova, E.V. Pilipenko, Proteasomes can degrade a signiﬁcant
proportion of cellular proteins independent of ubiquitination, J. Mol. Biol. 386
(2009) 814–827.
[13] P.A. Osmulski, M. Hochstrasser, M. Gaczynska, A tetrahedral transition state at the
active sites of the 20S proteasome is coupled to opening of the alpha-ring channel,
Structure 17 (2009) 1137–1147.
[14] M.H. Glickman, D.M. Rubin, O. Coux, I. Wefes, G. Pfeifer, Z. Cjeka, W. Baumeister,
V.A. Fried, D. Finley, A subcomplex of the proteasome regulatory particle required
for ubiquitin-conjugate degradation and related to the COP9-signalosome and
eIF3, Cell 94 (1998) 615–623.
[15] G.C. Lander, E. Estrin, M.E. Matyskiela, C. Bashore, E. Nogales, A. Martin, Complete
subunit architecture of the proteasome regulatory particle, Nature 482 (2012)
186–191.
[16] F. Beck, P. Unverdorben, S. Bohn, A. Schweitzer, G. Pfeifer, E. Sakata, S. Nickell, J.M.
Plitzko, E. Villa, W. Baumeister, et al., Near-atomic resolution structural model of
the yeast 26S proteasome, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 14870–14875.
[17] P. Sledz, P. Unverdorben, F. Beck, G. Pfeifer, A. Schweitzer, F. Forster, W. Baumeister,
Structure of the 26S proteasome with ATP-gammaS bound provides insights into
the mechanism of nucleotide-dependent substrate translocation, Proc. Natl. Acad.
Sci. U. S. A. 110 (2013) 7264–7269.
[18] K. Husnjak, S. Elsasser, N. Zhang, X. Chen, L. Randles, Y. Shi, K. Hofmann, K.J.
Walters, D. Finley, I. Dikic, Proteasome subunit Rpn13 is a novel ubiquitin receptor,
Nature 453 (2008) 481–488.
[19] G.R. Pathare, I. Nagy, S. Bohn, P. Unverdorben, A. Hubert, R. Korner, S. Nickell, K.
Lasker, A. Sali, T. Tamura, et al., The proteasomal subunit Rpn6 is a molecular
clamp holding the core and regulatory subcomplexes together, Proc. Natl. Acad.
Sci. U. S. A. 109 (2012) 149–154.
[20] R. Verma, L. Aravind, R. Oania, W.H. McDonald, J.R. Yates 3rd, E.V. Koonin, R.J.
Deshaies, Role of Rpn11 metalloprotease in deubiquitination and degradation by
the 26S proteasome, Science 298 (2002) 611–615.
[21] T. Yao, R.E. Cohen, A cryptic protease couples deubiquitination and degradation by
the proteasome, Nature 419 (2002) 403–407.
[22] F. Forster, K. Lasker, F. Beck, S. Nickell, A. Sali, W. Baumeister, An atomic model
AAA-ATPase/20S core particle sub-complex of the 26S proteasome, Biochem.
Biophys. Res. Commun. 388 (2009) 228–233.
[23] M.E. Matyskiela, G.C. Lander, A. Martin, Conformational switching of the 26S
proteasome enables substrate degradation,Nat. Struct.Mol. Biol. 20 (2013) 781–788.
[24] D.M. Smith, S.C. Chang, S. Park, D. Finley, Y. Cheng, A.L. Goldberg, Docking of the
proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens
the gate for substrate entry, Mol. Cell 27 (2007) 731–744.
[25] D. Thompson, K. Hakala, G.N. DeMartino, Subcomplexes of PA700, the 19 S regulator
of the 26 S proteasome, reveal relative roles of AAA subunits in 26 S proteasome as-
sembly and activation and ATPase activity, J. Biol. Chem. 284 (2009) 24891–24903.[26] T. Dange, D. Smith, T. Noy, P.C. Rommel, L. Jurzitza, R.J. Cordero, A. Legendre, D.
Finley, A.L. Goldberg, M. Schmidt, Blm10 protein promotes proteasomal substrate
turnover by an active gating mechanism, J. Biol. Chem. 286 (2011) 42830–42839.
[27] K. Sadre-Bazzaz, F.G. Whitby, H. Robinson, T. Formosa, C.P. Hill, Structure of a
Blm10 complex reveals common mechanisms for proteasome binding and gate
opening, Mol. Cell 37 (2010) 728–735.
[28] D. Barthelme, R.T. Sauer, Identiﬁcation of the Cdc48*20S proteasome as an ancient
AAA+ proteolytic machine, Science 337 (2012) 843–846.
[29] B.C. Braun, M. Glickman, R. Kraft, B. Dahlmann, P.M. Kloetzel, D. Finley, M. Schmidt,
The base of the proteasome regulatory particle exhibits chaperone-like activity,
Nat. Cell Biol. 1 (1999) 221–226.
[30] E. Strickland, K. Hakala, P.J. Thomas, G.N. DeMartino, Recognition of misfolding
proteins by PA700, the regulatory subcomplex of the 26 S proteasome, J. Biol.
Chem. 275 (2000) 5565–5572.
[31] J. Blickwedehl, M. Agarwal, C. Seong, R.K. Pandita, T. Melendy, P. Sung, T.K. Pandita,
N. Bangia, Role for proteasome activator PA200 and postglutamyl proteasome ac-
tivity in genomic stability, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 16165–16170.
[32] M. Schmidt, W. Haas, B. Crosas, P.G. Santamaria, S.P. Gygi, T. Walz, D. Finley, The
HEAT repeat protein Blm10 regulates the yeast proteasome by capping the core
particle, Nat. Struct. Mol. Biol. 12 (2005) 294–303.
[33] A.J. Marques, C. Glanemann, P.C. Ramos, R.J. Dohmen, The C-terminal extension of
the beta7 subunit and activator complexes stabilize nascent 20 S proteasomes and
promote their maturation, J. Biol. Chem. 282 (2007) 34869–34876.
[34] M. Fehlker, P. Wendler, A. Lehmann, C. Enenkel, Blm3 is part of nascent
proteasomes and is involved in a late stage of nuclear proteasome assembly,
EMBO Rep. 4 (2003) 959–963.
[35] A.D. Lopez, K. Tar, U. Krugel, T. Dange, I.G. Ros, M. Schmidt, Proteasomal degrada-
tion of Sfp1 contributes to the repression of ribosome biogenesis during starvation
and is mediated by the proteasome activator Blm10, Mol. Biol. Cell 22 (2011)
528–540.
[36] B. Khor, A.L. Bredemeyer, C.Y. Huang, I.R. Turnbull, R. Evans, L.B. Maggi Jr., J.M.
White, L.M. Walker, K. Carnes, R.A. Hess, et al., Proteasome activator PA200 is
required for normal spermatogenesis, Mol. Cell. Biol. 26 (2006) 2999–3007.
[37] K.M. Doherty, L.D. Pride, J. Lukose, B.E. Snydsman, R. Charles, A. Pramanik, E.G.
Muller, D. Botstein, C.W.Moore, Loss of a 20Sproteasome activator in Saccharomyces
cerevisiae downregulates genes important for genomic integrity, increases DNA
damage, and selectively sensitizes cells to agents with diverse mechanisms of ac-
tion, G3 (Bethesda) 2 (2012) 943–959.
[38] J. Blickwedehl, S. McEvoy, I. Wong, P. Kousis, J. Clements, R. Elliott, P. Cresswell, P.
Liang, N. Bangia, Proteasomes and proteasome activator 200 kDa (PA200) accumu-
late on chromatin in response to ionizing radiation, Radiat. Res. 167 (2007)
663–674.
[39] M.X. Qian, Y. Pang, C.H. Liu, K. Haratake, B.Y. Du, D.Y. Ji, G.F. Wang, Q.Q. Zhu, W.
Song, Y. Yu, et al., Acetylation-mediated proteasomal degradation of core histones
during DNA repair and spermatogenesis, Cell 153 (2013) 1012–1024.
[40] A. Forster, E.I. Masters, F.G. Whitby, H. Robinson, C.P. Hill, The 1.9 Ǻ structure of a
proteasome-11S activator complex and implications for proteasome–PAN/PA700
interactions, Mol. Cell 18 (2005) 589–599.
[41] W. Dubiel, G. Pratt, K. Ferrell, M. Rechsteiner, Puriﬁcation of an 11 S regulator of the
multicatalytic protease, J. Biol. Chem. 267 (1992) 22369–22377.
[42] C.P. Ma, C.A. Slaughter, G.N. DeMartino, Identiﬁcation, puriﬁcation, and character-
ization of a protein activator (PA28) of the 20 S proteasome (macropain), J. Biol.
Chem. 267 (1992) 10515–10523.
[43] N. Tanahashi, Y. Murakami, Y. Minami, N. Shimbara, K.B. Hendil, K. Tanaka, Hybrid
proteasomes. Induction by interferon-gamma and contribution to ATP-dependent
proteolysis, J. Biol. Chem. 275 (2000) 14336–14345.
[44] F. Kopp, B. Dahlmann, L. Kuehn, Reconstitution of hybrid proteasomes from
puriﬁed PA700–20 S complexes and PA28alphabeta activator: ultrastructure and
peptidase activities, J. Mol. Biol. 313 (2001) 465–471.
[45] P. Cascio, M. Call, B.M. Petre, T. Walz, A.L. Goldberg, Properties of the hybrid form of
the 26S proteasome containing both 19S and PA28 complexes, EMBO J. 21 (2002)
2636–2645.
[46] C. Realini, C.C. Jensen, Z. Zhang, S.C. Johnston, J.R. Knowlton, C.P. Hill, M.
Rechsteiner, Characterization of recombinant REGalpha, REGbeta, and REGgamma
proteasome activators, J. Biol. Chem. 272 (1997) 25483–25492.
[47] A. Sijts, Y. Sun, K. Janek, S. Kral, A. Paschen, D. Schadendorf, P.M. Kloetzel, The role
of the proteasome activator PA28 inMHC class I antigen processing, Mol. Immunol.
39 (2002) 165–169.
[48] C. Noda, N. Tanahashi, N. Shimbara, K.B. Hendil, K. Tanaka, Tissue distribution
of constitutive proteasomes, immunoproteasomes, and PA28 in rats, Biochem.
Biophys. Res. Commun. 277 (2000) 348–354.
[49] S. Murata, H. Kawahara, S. Tohma, K. Yamamoto, M. Kasahara, Y. Nabeshima, K.
Tanaka, T. Chiba, Growth retardation in mice lacking the proteasome activator
PA28gamma, J. Biol. Chem. 274 (1999) 38211–38215.
[50] X. Li, L. Amazit, W. Long, D.M. Lonard, J.J. Monaco, B.W. O'Malley, Ubiquitin- and
ATP-independent proteolytic turnover of p21 by the REGgamma–proteasome
pathway, Mol. Cell 26 (2007) 831–842.
[51] X. Chen, L.F. Barton, Y. Chi, B.E. Clurman, J.M. Roberts, Ubiquitin-independent deg-
radation of cell-cycle inhibitors by the REGgamma proteasome, Mol. Cell 26 (2007)
843–852.
[52] M.G. Brown, J. Driscoll, J.J. Monaco, Structural and serological similarity of
MHC-linked LMP and proteasome (multicatalytic proteinase) complexes, Nature
353 (1991) 355–357.
[53] V. Ortiz-Navarrete, A. Seelig, M. Gernold, S. Frentzel, P.M. Kloetzel, G.J. Hammerling,
Subunit of the ‘20S’ proteasome (multicatalytic proteinase) encoded by the major
histocompatibility complex, Nature 353 (1991) 662–664.
23M. Schmidt, D. Finley / Biochimica et Biophysica Acta 1843 (2014) 13–25[54] M. Groettrup, R. Kraft, S. Kostka, S. Standera, R. Stohwasser, P.M. Kloetzel, A third
interferon-gamma-induced subunit exchange in the 20S proteasome, Eur. J.
Immunol. 26 (1996) 863–869.
[55] D. Nandi, H. Jiang, J.J. Monaco, Identiﬁcation of MECL-1 (LMP-10) as the third
IFN-gamma-inducible proteasome subunit, J. Immunol. 156 (1996) 2361–2364.
[56] E.M. Huber, M. Basler, R. Schwab, W. Heinemeyer, C.J. Kirk, M. Groettrup, M. Groll,
Immuno- and constitutive proteasome crystal structures reveal differences in
substrate and inhibitor speciﬁcity, Cell 148 (2012) 727–738.
[57] D.A. Ferrington, D.S. Gregerson, Immunoproteasomes: structure, function, and
antigen presentation, Prog. Mol. Biol. Transl. Sci. 109 (2012) 75–112.
[58] A.M. Pickering, K.J. Davies, Differential roles of proteasomeand immunoproteasome
regulators Pa28alphabeta, Pa28gamma and Pa200 in the degradation of oxidized
proteins, Arch. Biochem. Biophys. 523 (2012) 181–190.
[59] U. Seifert, L.P. Bialy, F. Ebstein, D. Bech-Otschir, A. Voigt, F. Schroter, T. Prozorovski,
N. Lange, J. Steffen, M. Rieger, et al., Immunoproteasomes preserve protein homeo-
stasis upon interferon-induced oxidative stress, Cell 142 (2010) 613–624.
[60] A. Kitamura, Y. Maekawa, H. Uehara, K. Izumi, I. Kawachi, M. Nishizawa, Y.
Toyoshima, H. Takahashi, D.M. Standley, K. Tanaka, et al., A mutation in the
immunoproteasome subunit PSMB8 causes autoinﬂammation and lipodystrophy
in humans, J. Clin. Invest. 121 (2011) 4150–4160.
[61] J.A. Nathan, V. Spinnenhirn, G. Schmidtke, M. Basler, M. Groettrup, A.L. Goldberg,
Immuno- and constitutive proteasomes do not differ in their abilities to degrade
ubiquitinated proteins, Cell 152 (2013) 1184–1194.
[62] S. Murata, K. Sasaki, T. Kishimoto, S. Niwa, H. Hayashi, Y. Takahama, K. Tanaka,
Regulation of CD8+ T cell development by thymus-speciﬁc proteasomes, Science
316 (2007) 1349–1353.
[63] T. Nitta, S. Murata, K. Sasaki, H. Fujii, A.M. Ripen, N. Ishimaru, S. Koyasu, K. Tanaka,
Y. Takahama, Thymoproteasome shapes immunocompetent repertoire of CD8+
T cells, Immunity 32 (2010) 29–40.
[64] Q. Deveraux, V. Ustrell, C. Pickart, M. Rechsteiner, A 26 S protease subunit that
binds ubiquitin conjugates, J. Biol. Chem. 269 (1994) 7059–7061.
[65] S. Elsasser, D. Chandler-Militello, B. Muller, J. Hanna, D. Finley, Rad23 and Rpn10
serve as alternative ubiquitin receptors for the proteasome, J. Biol. Chem. 279
(2004) 26817–26822.
[66] Y. Matiuhin, D.S. Kirkpatrick, I. Ziv, W. Kim, A. Dakshinamurthy, O. Kleifeld,
S.P. Gygi, N. Reis, M.H. Glickman, Extraproteasomal Rpn10 restricts access
of the polyubiquitin-binding protein Dsk2 to proteasome, Mol. Cell 32 (2008)
415–425.
[67] O. Voloshin, A. Bakhrat, S. Herrmann, D. Raveh, Transfer of Ho endonuclease and
Ufo1 to the proteasome by the UbL–UbA shuttle protein, Ddi1, analysed by com-
plex formation in vitro, PLoS One 7 (2012) e39210.
[68] J. Hanna, N.A. Hathaway, Y. Tone, B. Crosas, S. Elsasser, D.S. Kirkpatrick, D.S. Leggett,
S.P. Gygi, R.W. King, D. Finley, Deubiquitinating enzyme Ubp6 functions
noncatalytically to delay proteasomal degradation, Cell 127 (2006) 99–111.
[69] E. Koulich, X. Li, G.N. DeMartino, Relative structural and functional roles of multiple
deubiquitylating proteins associated with mammalian 26S proteasome, Mol. Biol.
Cell 19 (2008) 1072–1082.
[70] B.H. Lee, M.J. Lee, S. Park, D.C. Oh, S. Elsasser, P.C. Chen, C. Gartner, N. Dimova, J.
Hanna, S.P. Gygi, et al., Enhancement of proteasome activity by a small-molecule
inhibitor of USP14, Nature 467 (2010) 179–184.
[71] Y.A. Lam, W. Xu, G.N. DeMartino, R.E. Cohen, Editing of ubiquitin conjugates by an
isopeptidase in the 26S proteasome, Nature 385 (1997) 737–740.
[72] S. Elsasser, R.R. Gali, M. Schwickart, C.N. Larsen, D.S. Leggett, B. Muller, M.T. Feng, F.
Tubing, G.A. Dittmar, D. Finley, Proteasome subunit Rpn1 binds ubiquitin-like
protein domains, Nat. Cell Biol. 4 (2002) 725–730.
[73] J. Hanna, D.S. Leggett, D. Finley, Ubiquitin depletion as a key mediator of toxicity by
translational inhibitors, Mol. Cell. Biol. 23 (2003) 9251–9261.
[74] B. Crosas, J. Hanna, D.S. Kirkpatrick, D.P. Zhang, Y. Tone, N.A. Hathaway, C. Buecker,
D.S. Leggett, M. Schmidt, R.W. King, et al., Ubiquitin chains are remodeled at the
proteasome by opposing ubiquitin ligase and deubiquitinating activities, Cell 127
(2006) 1401–1413.
[75] N.N. Fang, A.H. Ng, V. Measday, T. Mayor, Hul5 HECT ubiquitin ligase plays a major
role in the ubiquitylation and turnover of cytosolic misfolded proteins, Nat. Cell
Biol. 13 (2011) 1344–1352.
[76] Y. Xie, A. Varshavsky, Physical association of ubiquitin ligases and the 26S
proteasome, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2497–2502.
[77] S.J. Lee, D. Choi, H. Rhim, S. Kang, E3 ubiquitin ligase RNF2 interacts with the
S6' proteasomal ATPase subunit and increases the ATP hydrolysis activity of S6',
Biochem. J. 389 (2005) 457–463.
[78] M. Loscher, K. Fortschegger, G. Ritter, M. Wostry, R. Voglauer, J.A. Schmid, S.
Watters, A.J. Rivett, P. Ajuh, A.I. Lamond, et al., Interaction of U-box E3 ligase
SNEV with PSMB4, the beta7 subunit of the 20 S proteasome, Biochem. J. 388
(2005) 593–603.
[79] M. Seeger, R. Hartmann-Petersen, C.R. Wilkinson, M. Wallace, I. Samejima, M.S.
Taylor, C. Gordon, Interaction of the anaphase-promoting complex/cyclosome
and proteasome protein complexes with multiubiquitin chain-binding proteins,
J. Biol. Chem. 278 (2003) 16791–16796.
[80] R. Verma, S. Chen, R. Feldman, D. Schieltz, J. Yates, J. Dohmen, R.J. Deshaies,
Proteasomal proteomics: identiﬁcation of nucleotide-sensitive proteasome-
interactingproteins bymass spectrometric analysis of afﬁnity-puriﬁedproteasomes,
Mol. Biol. Cell 11 (2000) 3425–3439.
[81] J.W. Um, E. Im, H.J. Lee, B. Min, L. Yoo, J. Yoo, H. Lubbert, C. Stichel-Gunkel, H.S. Cho,
J.B. Yoon, et al., Parkin directly modulates 26S proteasome activity, J. Neurosci. 30
(2010) 11805–11814.
[82] Y. Xie, A. Varshavsky, UFD4 lacking the proteasome-binding region catalyses
ubiquitination but is impaired in proteolysis, Nat. Cell Biol. 4 (2002) 1003–1007.[83] A.R. Kusmierczyk, M.J. Kunjappu, R.Y. Kim, M. Hochstrasser, A conserved 20S
proteasome assembly factor requires a C-terminal HbYX motif for proteasomal
precursor binding, Nat. Struct. Mol. Biol. 18 (2011) 622–629.
[84] S.L. McCutchen-Maloney, K. Matsuda, N. Shimbara, D.D. Binns, K. Tanaka, C.A.
Slaughter, G.N. DeMartino, cDNA cloning, expression, and functional characteriza-
tion of PI31, a proline-rich inhibitor of the proteasome, J. Biol. Chem. 275 (2000)
18557–18565.
[85] D.M. Zaiss, S. Standera, H. Holzhutter, P. Kloetzel, A.J. Sijts, The proteasome inhibitor
PI31 competes with PA28 for binding to 20S proteasomes, FEBS Lett. 457 (1999)
333–338.
[86] D.M. Zaiss, S. Standera, P.M. Kloetzel, A.J. Sijts, PI31 is a modulator of proteasome
formation and antigen processing, Proc. Natl. Acad. Sci. U. S. A. 99 (2002)
14344–14349.
[87] M. Bader, S. Benjamin, O.L. Wapinski, D.M. Smith, A.L. Goldberg, H. Steller, A con-
served F box regulatory complex controls proteasome activity in Drosophila, Cell
145 (2011) 371–382.
[88] K. Yamanaka, Y. Sasagawa, T. Ogura, Recent advances in p97/VCP/Cdc48 cellular
functions, Biochim. Biophys. Acta 1823 (2012) 130–137.
[89] A. Buchberger, Roles of cdc48 in regulated protein degradation in yeast, Subcell.
Biochem. 66 (2013) 195–222.
[90] D. Barthelme, R.T. Sauer, Bipartite determinants mediate an evolutionarily con-
served interaction between Cdc48 and the 20S peptidase, Proc. Natl. Acad. Sci.
U. S. A. 110 (2013) 3327–3332.
[91] K. Tan, T. Shlomi, H. Feizi, T. Ideker, R. Sharan, Transcriptional regulation of protein
complexes within and across species, Proc. Natl. Acad. Sci. U. S. A. 104 (2007)
1283–1288.
[92] S. Meiners, D. Heyken, A. Weller, A. Ludwig, K. Stangl, P.M. Kloetzel, E. Kruger,
Inhibition of proteasome activity induces concerted expression of proteasome
genes and de novo formation of mammalian proteasomes, J. Biol. Chem. 278
(2003) 21517–21525.
[93] G. Mannhaupt, R. Schnall, V. Karpov, I. Vetter, H. Feldmann, Rpn4p acts as a tran-
scription factor by binding to PACE, a nonamer box found upstream of 26S
proteasomal and other genes in yeast, FEBS Lett. 450 (1999) 27–34.
[94] D.S. Leggett, J. Hanna, A. Borodovsky, B. Crosas, M. Schmidt, R.T. Baker, T. Walz, H.
Ploegh, D. Finley, Multiple associated proteins regulate proteasome structure and
function, Mol. Cell 10 (2002) 495–507.
[95] S.A. Jelinsky, P. Estep, G.M. Church, L.D. Samson, Regulatory networks revealed by
transcriptional proﬁling of damaged Saccharomyces cerevisiae cells: Rpn4 links
base excision repair with proteasomes, Mol. Cell. Biol. 20 (2000) 8157–8167.
[96] D. Ju, L.Wang, X.Mao, Y. Xie, Homeostatic regulation of theproteasome via anRpn4-
dependent feedback circuit, Biochem. Biophys. Res. Commun. 321 (2004) 51–57.
[97] D. Ju, Y. Xie, Proteasomal degradation of RPN4 via two distinct mechanisms,
ubiquitin-dependent and -independent, J. Biol. Chem. 279 (2004) 23851–23854.
[98] L. Wang, X. Mao, D. Ju, Y. Xie, Rpn4 is a physiological substrate of the Ubr2
ubiquitin ligase, J. Biol. Chem. 279 (2004) 55218–55223.
[99] M. Ma, Z.L. Liu, Comparative transcriptome proﬁling analyses during the lag phase
uncover YAP1, PDR1, PDR3, RPN4, and HSF1 as key regulatory genes in genomic
adaptation to the lignocellulose derived inhibitor HMF for Saccharomyces cerevisiae,
BMC Genomics 11 (2010) 660.
[100] S.K. Radhakrishnan, C.S. Lee, P. Young, A. Beskow, J.Y. Chan, R.J. Deshaies, Transcrip-
tion factor Nrf1mediates the proteasome recovery pathway after proteasome inhi-
bition in mammalian cells, Mol. Cell 38 (2010) 17–28.
[101] J. Steffen,M. Seeger, A. Koch, E. Kruger, Proteasomal degradation is transcriptionally
controlled by TCF11 via an ERAD-dependent feedback loop, Mol. Cell 40 (2010)
147–158.
[102] D.C. Kraft, C.C. Deocaris, R.Wadhwa, S.I. Rattan, Preincubationwith the proteasome
inhibitor MG-132 enhances proteasome activity via the Nrf2 transcription factor in
aging human skin ﬁbroblasts, Ann. N. Y. Acad. Sci. 1067 (2006) 420–424.
[103] A.M. Pickering, R.A. Linder, H. Zhang, H.J. Forman, K.J. Davies, Nrf2-dependent in-
duction of proteasome and Pa28alphabeta regulator are required for adaptation
to oxidative stress, J. Biol. Chem. 287 (2012) 10021–10031.
[104] S. Kapeta, N. Chondrogianni, E.S. Gonos, Nuclear erythroid factor 2-mediated
proteasome activation delays senescence in human ﬁbroblasts, J. Biol. Chem. 285
(2010) 8171–8184.
[105] M.K. Kwak, N. Wakabayashi, J.L. Greenlaw, M. Yamamoto, T.W. Kensler, Antioxi-
dants enhance mammalian proteasome expression through the Keap1–Nrf2
signaling pathway, Mol. Cell. Biol. 23 (2003) 8786–8794.
[106] G.P. Sykiotis, D. Bohmann, Stress-activated cap‘n’collar transcription factors in aging
and human disease, Sci. Signal. 3 (2010) re3.
[107] M. Ohtsuji, F. Katsuoka, A. Kobayashi, H. Aburatani, J.D. Hayes, M. Yamamoto, Nrf1
and Nrf2 play distinct roles in activation of antioxidant response element-
dependent genes, J. Biol. Chem. 283 (2008) 33554–33562.
[108] W. Wang, J.Y. Chan, Nrf1 is targeted to the endoplasmic reticulum membrane by
an N-terminal transmembrane domain. Inhibition of nuclear translocation and
transacting function, J. Biol. Chem. 281 (2006) 19676–19687.
[109] S.C. Lo, M. Hannink, PGAM5 tethers a ternary complex containing Keap1 and Nrf2
to mitochondria, Exp. Cell Res. 314 (2008) 1789–1803.
[110] J.Y. Chan, M. Kwong, R. Lu, J. Chang, B. Wang, T.S. Yen, Y.W. Kan, Targeted disrup-
tion of the ubiquitous CNC-bZIP transcription factor, Nrf-1, results in anemia and
embryonic lethality in mice, EMBO J. 17 (1998) 1779–1787.
[111] A.F. Hubbs, S.A. Benkovic, D.B.Miller, J.P. O'Callaghan, L. Battelli, D. Schwegler-Berry,
Q. Ma, Vacuolar leukoencephalopathywith widespread astrogliosis inmice lacking
transcription factor Nrf2, Am. J. Pathol. 170 (2007) 2068–2076.
[112] K. Yoh, K. Itoh, A. Enomoto, A. Hirayama, N. Yamaguchi, M. Kobayashi, N. Morito,
A. Koyama, M. Yamamoto, S. Takahashi, Nrf2-deﬁcient female mice develop
lupus-like autoimmune nephritis, Kidney Int. 60 (2001) 1343–1353.
24 M. Schmidt, D. Finley / Biochimica et Biophysica Acta 1843 (2014) 13–25[113] Y. Tsuchiya, T. Morita, M. Kim, S. Iemura, T. Natsume, M. Yamamoto, A. Kobayashi,
Dual regulation of the transcriptional activity of Nrf1 by beta-TrCP- and Hrd1-
dependent degradation mechanisms, Mol. Cell. Biol. 31 (2011) 4500–4512.
[114] M. Furukawa, Y. Xiong, BTB protein Keap1 targets antioxidant transcription factor
Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase, Mol. Cell. Biol. 25 (2005)
162–171.
[115] N.W. Kahn, S.L. Rea, S. Moyle, A. Kell, T.E. Johnson, Proteasomal dysfunction acti-
vates the transcription factor SKN-1 and produces a selective oxidative-stress
response in Caenorhabditis elegans, Biochem. J. 409 (2008) 205–213.
[116] X. Li, O. Matilainen, C. Jin, K.M. Glover-Cutter, C.I. Holmberg, T.K. Blackwell, Speciﬁc
SKN-1/Nrf stress responses to perturbations in translation elongation and
proteasome activity, PLoS Genet. 7 (2011) e1002119.
[117] A.M. Pickering, T.A. Staab, J. Tower, D.S. Sieburth, K.J. Davies, A conserved role for
the 20S proteasome and Nrf2 transcription factor in oxidative-stress adaptation
in mammals, C. elegans and D. melanogaster, J. Exp. Biol. 216 (2012) 543–553.
[118] K.P. Choe, A.J. Przybysz, K. Strange, The WD40 repeat protein WDR-23 functions
with the CUL4/DDB1 ubiquitin ligase to regulate nuclear abundance and activity
of SKN-1 in Caenorhabditis elegans, Mol. Cell. Biol. 29 (2009) 2704–2715.
[119] W. Niu, Z.J. Lu, M. Zhong, M. Sarov, J.I. Murray, C.M. Brdlik, J. Janette, C. Chen, P.
Alves, E. Preston, et al., Diverse transcription factor binding features revealed by
genome-wide ChIP-seq in C. elegans, Genome Res. 21 (2011) 245–254.
[120] D. Vilchez, I. Morantte, Z. Liu, P.M. Douglas, C. Merkwirth, A.P. Rodrigues, G.
Manning, A. Dillin, RPN-6 determines C. elegans longevity under proteotoxic stress
conditions, Nature 489 (2012) 263–268.
[121] H. Huang, D.J. Tindall, Regulation of FOXO protein stability via ubiquitination and
proteasome degradation, Biochim. Biophys. Acta 1813 (2011) 1961–1964.
[122] J. Zhao, J.J. Brault, A. Schild, A.L. Goldberg, Coordinate activation of autophagy and the
proteasome pathway by FoxO transcription factor, Autophagy 4 (2008) 378–380.
[123] J. Kikuchi, Y. Iwafune, T. Akiyama, A. Okayama, H. Nakamura, N. Arakawa, Y.
Kimura, H. Hirano, Co- and post-translational modiﬁcations of the 26S proteasome
in yeast, Proteomics 10 (2010) 2769–2779.
[124] A.V. Gomes, C. Zong, R.D. Edmondson, X. Li, E. Stefani, J. Zhang, R.C. Jones, S.
Thyparambil, G.W. Wang, X. Qiao, et al., Mapping the murine cardiac 26S
proteasome complexes, Circ. Res. 99 (2006) 362–371.
[125] F. Zhang, K. Su, X. Yang, D.B. Bowe, A.J. Paterson, J.E. Kudlow, O-GlcNAc modiﬁca-
tion is an endogenous inhibitor of the proteasome, Cell 115 (2003) 715–725.
[126] A.L. Bulteau, K.C. Lundberg, K.M. Humphries, H.A. Sadek, P.A. Szweda, B. Friguet, L.I.
Szweda, Oxidative modiﬁcation and inactivation of the proteasome during coro-
nary occlusion/reperfusion, J. Biol. Chem. 276 (2001) 30057–30063.
[127] G. Carrard,M. Dieu,M. Raes, O. Toussaint, B. Friguet, Impact of ageing on proteasome
structure and function in human lymphocytes, Int. J. Biochem. Cell Biol. 35 (2003)
728–739.
[128] X. Wang, J. Yen, P. Kaiser, L. Huang, Regulation of the 26S proteasome complex
during oxidative stress, Sci. Signal. 3 (2010) ra88.
[129] A. Kimura, Y. Kato, H. Hirano, N-myristoylation of theRpt2 subunit regulates intracel-
lular localization of the yeast 26S proteasome, Biochemistry 51 (2012) 8856–8866.
[130] M. Isasa, E.J. Katz, W. Kim, V. Yugo, S. Gonzalez, D.S. Kirkpatrick, T.M. Thomson, D.
Finley, S.P. Gygi, B. Crosas, Monoubiquitination of RPN10 regulates substrate
recruitment to the proteasome, Mol. Cell 38 (2010) 733–745.
[131] Z. Lipinszki, L. Kovacs, P. Deak, A. Udvardy, Ubiquitylation of Drosophila p54/
Rpn10/S5a regulates its interaction with the UBA–UBL polyubiquitin receptors,
Biochemistry 51 (2012) 2461–2470.
[132] G.M. Silva, L.E. Netto, V. Simoes, L.F. Santos, F.C. Gozzo, M.A. Demasi, C.L. Oliveira,
R.N. Bicev, C.F. Klitzke, M.C. Sogayar, et al., Redox control of 20S proteasome gating,
Antioxid. Redox Signal. 16 (2012) 1183–1194.
[133] O. Ullrich, T. Reinheckel, N. Sitte, R. Hass, T. Grune, K.J. Davies, Poly-ADP ribose po-
lymerase activates nuclear proteasome to degrade oxidatively damaged histones,
Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 6223–6228.
[134] P.F. Cho-Park, H. Steller, Proteasome regulation by ADP-ribosylation, Cell 153
(2013) 614–627.
[135] F. Zhang, Y. Hu, P. Huang, C.A. Toleman, A.J. Paterson, J.E. Kudlow, Proteasome func-
tion is regulated by cyclic AMP-dependent protein kinase through phosphorylation
of Rpt6, J. Biol. Chem. 282 (2007) 22460–22471.
[136] C. Zong, A.V. Gomes, O. Drews, X. Li, G.W. Young, B. Berhane, X. Qiao, S.W. French, F.
Bardag-Gorce, P. Ping, Regulation of murine cardiac 20S proteasomes: role of asso-
ciating partners, Circ. Res. 99 (2006) 372–380.
[137] M.E. Pereira, S. Wilk, Phosphorylation of the multicatalytic proteinase complex
from bovine pituitaries by a copurifying cAMP-dependent protein kinase, Arch.
Biochem. Biophys. 283 (1990) 68–74.
[138] M. Asai, O. Tsukamoto, T. Minamino, H. Asanuma, M. Fujita, Y. Asano, H. Takahama,
H. Sasaki, S. Higo, M. Asakura, et al., PKA rapidly enhances proteasome assembly
and activity in in vivo canine hearts, J. Mol. Cell. Cardiol. 46 (2009) 452–462.
[139] S.N. Djakovic, E.M. Marquez-Lona, S.K. Jakawich, R. Wright, C. Chu, M.A. Sutton,
G.N. Patrick, Phosphorylation of Rpt6 regulates synaptic strength in hippocampal
neurons, J. Neurosci. 32 (2012) 5126–5131.
[140] K. Satoh, H. Sasajima, K.I. Nyoumura, H. Yokosawa, H. Sawada, Assembly of the
26S proteasome is regulated by phosphorylation of the p45/Rpt6 ATPase subunit,
Biochemistry 40 (2001) 314–319.
[141] X. Liu, W. Huang, C. Li, P. Li, J. Yuan, X. Li, X.B. Qiu, Q. Ma, C. Cao, Interaction be-
tween c-Abl and Arg tyrosine kinases and proteasome subunit PSMA7 regulates
proteasome degradation, Mol. Cell 22 (2006) 317–327.
[142] S.H. Lee, Y. Park, S.K. Yoon, J.B. Yoon, Osmotic stress inhibits proteasome by p38
MAPK-dependent phosphorylation, J. Biol. Chem. 285 (2010) 41280–41289.
[143] C.J. Ramnanan, M.E. Allan, A.G. Groom, K.B. Storey, Regulation of global protein
translation and protein degradation in aerobic dormancy, Mol. Cell. Biochem. 323
(2009) 9–20.[144] X. Guo, J.L. Engel, J. Xiao, V.S. Tagliabracci, X.Wang, L. Huang, J.E. Dixon, UBLCP1 is a
26S proteasome phosphatase that regulates nuclear proteasome activity, Proc.
Natl. Acad. Sci. U. S. A. 108 (2011) 18649–18654.
[145] J. Delic, P. Masdehors, S. Omura, J.M. Cosset, J. Dumont, J.L. Binet, H. Magdelenat,
The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo-
and radioresistant human chronic lymphocytic leukaemia lymphocytes to
TNF-alpha-initiated apoptosis, Br. J. Cancer 77 (1998) 1103–1107.
[146] R.Z. Orlowski, J.R. Eswara, A. Lafond-Walker, M.R. Grever, M. Orlowski, C.V. Dang,
Tumor growth inhibition induced in amurinemodel of human Burkitt's lymphoma
by a proteasome inhibitor, Cancer Res. 58 (1998) 4342–4348.
[147] L. Chen, K. Madura, Increased proteasome activity, ubiquitin-conjugating enzymes,
and eEF1A translation factor detected in breast cancer tissue, Cancer Res. 65 (2005)
5599–5606.
[148] R.Z. Orlowski, T.E. Stinchcombe, B.S. Mitchell, T.C. Shea, A.S. Baldwin, S. Stahl, J.
Adams, D.L. Esseltine, P.J. Elliott, C.S. Pien, et al., Phase I trial of the proteasome in-
hibitor PS-341 in patients with refractory hematologic malignancies, J. Clin. Oncol.
20 (2002) 4420–4427.
[149] S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin, P.G. Richardson, R.
Niesvizky, R. Alexanian, S.A. Limentani, M. Alsina, et al., A phase 2 study of two
doses of bortezomib in relapsed or refractory myeloma, Br. J. Haematol. 127
(2004) 165–172.
[150] E.M. Huber, M. Groll, Inhibitors for the immuno- and constitutive proteasome: cur-
rent and future trends in drug development, Angew. Chem. Int. Ed. Engl. 51 (2012)
8708–8720.
[151] S. Frankland-Searby, S.R. Bhaumik, The 26S proteasome complex: an attractive
target for cancer therapy, Biochim. Biophys. Acta 1825 (2012) 64–76.
[152] Z. Wang, J. Yang, C. Kirk, Y. Fang, M. Alsina, A. Badros, K. Papadopoulos, A. Wong,
T. Woo, D. Bomba, et al., Clinical pharmacokinetics, metabolism, and drug–drug
interaction of carﬁlzomib, Drug Metab. Dispos. 41 (2013) 230–237.
[153] A. Nencioni, A. Garuti, K. Schwarzenberg, G. Cirmena, G. Dal Bello, I. Rocco, E.
Barbieri, P. Brossart, F. Patrone, A. Ballestrero, Proteasome inhibitor-induced apo-
ptosis in human monocyte-derived dendritic cells, Eur. J. Immunol. 36 (2006)
681–689.
[154] B. Blanco, L.I. Sanchez-Abarca, T. Caballero-Velazquez, C. Santamaria, S. Inoges, J.A.
Perez-Simon, Depletion of alloreactive T-cells in vitro using the proteasome inhib-
itor bortezomib preserves the immune response against pathogens, Leuk. Res. 35
(2011) 1412–1415.
[155] E. Moran, F. Carbone, V. Augusti, F. Patrone, A. Ballestrero, A. Nencioni, Proteasome
inhibitors as immunosuppressants: biological rationale and clinical experience,
Semin. Hematol. 49 (2012) 270–276.
[156] T. Muchamuel, M. Basler, M.A. Aujay, E. Suzuki, K.W. Kalim, C. Lauer, C. Sylvain, E.R.
Ring, J. Shields, J. Jiang, et al., A selective inhibitor of the immunoproteasome
subunit LMP7 blocks cytokine production and attenuates progression of experi-
mental arthritis, Nat. Med. 15 (2009) 781–787.
[157] M. Basler, M. Dajee, C. Moll, M. Groettrup, C.J. Kirk, Prevention of experimental
colitis by a selective inhibitor of the immunoproteasome, J. Immunol. 185 (2010)
634–641.
[158] Q. Huang, M.E. Figueiredo-Pereira, Ubiquitin/proteasome pathway impairment in
neurodegeneration: therapeutic implications, Apoptosis 15 (2010) 1292–1311.
[159] L.E. Hebert, J. Weuve, P.A. Scherr, D.A. Evans, Alzheimer disease in the United States
(2010–2050) estimated using the 2010 census, Neurology 80 (2013) 1778–1783.
[160] D.J. Selkoe, Alzheimer's disease, Cold Spring Harb. Perspect. Biol. 3 (2011).
[161] N. Iwata, M. Higuchi, T.C. Saido, Metabolism of amyloid-beta peptide and
Alzheimer's disease, Pharmacol. Ther. 108 (2005) 129–148.
[162] M. Kaneko, H. Koike, R. Saito, Y. Kitamura, Y. Okuma, Y. Nomura, Loss of HRD1-
mediated protein degradation causes amyloid precursor protein accumulation
and amyloid-beta generation, J. Neurosci. 30 (2010) 3924–3932.
[163] B.P. Tseng, K.N. Green, J.L. Chan, M. Blurton-Jones, F.M. LaFerla, Abeta inhibits the
proteasome and enhances amyloid and tau accumulation, Neurobiol. Aging 29
(2008) 1607–1618.
[164] Y. Takei, J. Teng, A. Harada, N. Hirokawa, Defects in axonal elongation and neuronal
migration in mice with disrupted tau and map1b genes, J. Cell Biol. 150 (2000)
989–1000.
[165] T. Grune, D. Botzen, M. Engels, P. Voss, B. Kaiser, T. Jung, S. Grimm, G. Ermak, K.J.
Davies, Tau protein degradation is catalyzed by the ATP/ubiquitin-independent
20S proteasome under normal cell conditions, Arch. Biochem. Biophys. 500 (2010)
181–188.
[166] M.J. Lee, J.H. Lee, D.C. Rubinsztein, Tau degradation: the ubiquitin–proteasome system
versus the autophagy–lysosome system, Prog. Neurobiol. 105 (2013) 600–604.
[167] S.W. Min, S.H. Cho, Y. Zhou, S. Schroeder, V. Haroutunian, W.W. Seeley, E.J. Huang,
Y. Shen, E. Masliah, C. Mukherjee, et al., Acetylation of tau inhibits its degradation
and contributes to tauopathy, Neuron 67 (2010) 953–966.
[168] L. Petrucelli, D. Dickson, K. Kehoe, J. Taylor, H. Snyder, A. Grover, M. De Lucia, E.
McGowan, J. Lewis, G. Prihar, et al., CHIP and Hsp70 regulate tau ubiquitination,
degradation and aggregation, Hum. Mol. Genet. 13 (2004) 703–714.
[169] C.A. Dickey, J. Koren, Y.J. Zhang, Y.F. Xu, U.K. Jinwal,M.J. Birnbaum, B.Monks,M. Sun,
J.Q. Cheng, C. Patterson, et al., Akt and CHIP coregulate tau degradation through
coordinated interactions, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3622–3627.
[170] S. Keck, R. Nitsch, T. Grune, O. Ullrich, Proteasome inhibition by paired helical
ﬁlament-tau in brains of patients with Alzheimer's disease, J. Neurochem. 85
(2003) 115–122.
[171] T. Bartels, J.G. Choi, D.J. Selkoe, alpha-Synuclein occurs physiologically as a helically
folded tetramer that resists aggregation, Nature 477 (2011) 107–110.
[172] G.K. Tofaris, R. Layﬁeld, M.G. Spillantini, alpha-Synuclein metabolism and aggrega-
tion is linked to ubiquitin-independent degradation by the proteasome, FEBS Lett.
509 (2001) 22–26.
25M. Schmidt, D. Finley / Biochimica et Biophysica Acta 1843 (2014) 13–25[173] L. Bedford, D. Hay, A. Devoy, S. Paine, D.G. Powe, R. Seth, T. Gray, I. Topham, K. Fone,
N. Rezvani, et al., Depletion of 26S proteasomes in mouse brain neurons causes
neurodegeneration and Lewy-like inclusions resembling human pale bodies,
J. Neurosci. 28 (2008) 8189–8198.
[174] S.M. Paine, G. Anderson, K. Bedford, K. Lawler, R.J. Mayer, J. Lowe, L. Bedford, Pale
body-like inclusion formation and neurodegeneration following depletion of 26S
proteasomes in mouse brain neurons are independent of alpha-synuclein, PLoS
One 8 (2013) e54711.
[175] C. Wahl, S. Kautzmann, G. Krebiehl, K. Strauss, D. Woitalla, T. Muller, P. Bauer, O.
Riess, R. Kruger, A comprehensive genetic study of the proteasomal subunit
S6 ATPase in German Parkinson's disease patients, J. Neural Transm. 115 (2008)
1141–1148.
[176] S. Schipper-Krom, K. Juenemann, E.A. Reits, The ubiquitin–proteasome system in
Huntington's disease: are proteasomes impaired, initiators of disease, or coming
to the rescue? Biochem. Res. Int. 2012 (2012) 837015.
[177] A novel gene containing a trinucleotide repeat that is expanded and unstable
on Huntington's disease chromosomes. The Huntington's Disease Collaborative
Research Group, Cell 72 (1993) 971–983.
[178] R.G. Snell, J.C. MacMillan, J.P. Cheadle, I. Fenton, L.P. Lazarou, P. Davies, M.E.
MacDonald, J.F. Gusella, P.S. Harper, D.J. Shaw, Relationship between trinucleotide
repeat expansion and phenotypic variation in Huntington's disease, Nat. Genet. 4
(1993) 393–397.
[179] I. Sanchez, C. Mahlke, J. Yuan, Pivotal role of oligomerization in expanded
polyglutamine neurodegenerative disorders, Nature 421 (2003) 373–379.
[180] J.M. Ordway, S. Tallaksen-Greene, C.A. Gutekunst, E.M. Bernstein, J.A. Cearley, H.W.
Wiener, L.S. Dure 4th, R. Lindsey, S.M. Hersch, R.S. Jope, et al., Ectopically expressed
CAG repeats cause intranuclear inclusions and a progressive late onset neurological
phenotype in the mouse, Cell 91 (1997) 753–763.
[181] M.A. Kalchman, R.K. Graham, G. Xia, H.B. Koide, J.G. Hodgson, K.C. Graham, Y.P.
Goldberg, R.D. Gietz, C.M. Pickart, M.R. Hayden, Huntingtin is ubiquitinated and
interacts with a speciﬁc ubiquitin-conjugating enzyme, J. Biol. Chem. 271 (1996)
19385–19394.
[182] M.S. Hipp, C.N. Patel, K. Bersuker, B.E. Riley, S.E. Kaiser, T.A. Shaler, M. Brandeis, R.R.
Kopito, Indirect inhibition of 26S proteasome activity in a cellular model of
Huntington's disease, J. Cell Biol. 196 (2012) 573–587.
[183] J.M. Hunter, M. Lesort, G.V. Johnson, Ubiquitin–proteasome system alterations in a
striatal cell model of Huntington's disease, J. Neurosci. Res. 85 (2007) 1774–1788.
[184] N.F. Bence, R.M. Sampat, R.R. Kopito, Impairment of the ubiquitin–proteasome sys-
tem by protein aggregation, Science 292 (2001) 1552–1555.
[185] C.I. Holmberg, K.E. Staniszewski, K.N. Mensah, A. Matouschek, R.I. Morimoto, Inef-
ﬁcient degradation of truncated polyglutamine proteins by the proteasome, EMBO
J. 23 (2004) 4307–4318.
[186] P. Venkatraman, R. Wetzel, M. Tanaka, N. Nukina, A.L. Goldberg, Eukaryotic
proteasomes cannot digest polyglutamine sequences and release them during deg-
radation of polyglutamine-containing proteins, Mol. Cell 14 (2004) 95–104.
[187] G. Pratt, M. Rechsteiner, Proteasomes cleave atmultiple sites within polyglutamine
tracts: activation by PA28gamma(K188E), J. Biol. Chem. 283 (2008) 12919–12925.
[188] H. Seo, K.C. Sonntag,W. Kim, E. Cattaneo, O. Isacson, Proteasome activator enhances
survival of Huntington's disease neuronal model cells, PLoS One 2 (2007) e238.
[189] H.R. Morris, A.J. Waite, N.M. Williams, J.W. Neal, D.J. Blake, Recent advances in
the genetics of the ALS–FTLD complex, Curr. Neurol. Neurosci. Rep. 12 (2012)
243–250.
[190] Y. Tashiro, M. Urushitani, H. Inoue, M. Koike, Y. Uchiyama, M. Komatsu, K. Tanaka, M.
Yamazaki,M. Abe, H.Misawa, et al.,Motor neuron-speciﬁc disruption of proteasomes,but not autophagy, replicates amyotrophic lateral sclerosis, J. Biol. Chem. 287 (2012)
42984–42994.
[191] S. Schlossarek, L. Carrier, The ubiquitin–proteasome system in cardiomyopathies,
Curr. Opin. Cardiol. 26 (2011) 190–195.
[192] S.R. Powell, J. Herrmann, A. Lerman, C. Patterson, X. Wang, The ubiquitin–
proteasome system and cardiovascular disease, Prog. Mol. Biol. Transl. Sci. 109
(2012) 295–346.
[193] Z. Tian, H. Zheng, J. Li, Y. Li, H. Su, X.Wang, Genetically inducedmoderate inhibition
of theproteasome in cardiomyocytes exacerbatesmyocardial ischemia–reperfusion
injury in mice, Circ. Res. 111 (2012) 532–542.
[194] J. Li, K.M. Horak, H. Su, A. Sanbe, J. Robbins, X. Wang, Enhancement of proteasomal
function protects against cardiac proteinopathy and ischemia/reperfusion injury in
mice, J. Clin. Invest. 121 (2011) 3689–3700.
[195] M.A. Baraibar, L. Liu, E.K. Ahmed, B. Friguet, Protein oxidative damage at the cross-
roads of cellular senescence, aging, and age-related diseases, Oxidative Med. Cell.
Longev. 2012 (2012) 919832.
[196] C.K. Lee, R.G. Klopp, R. Weindruch, T.A. Prolla, Gene expression proﬁle of aging and
its retardation by caloric restriction, Science 285 (1999) 1390–1393.
[197] V.A. Vernace, L. Arnaud, T. Schmidt-Glenewinkel, M.E. Figueiredo-Pereira, Aging
perturbs 26S proteasome assembly in Drosophila melanogaster, FASEB J. 21 (2007)
2672–2682.
[198] M. Bajorek, D. Finley, M.H. Glickman, Proteasome disassembly and downregulation
is correlatedwith viability during stationary phase, Curr. Biol. 13 (2003) 1140–1144.
[199] T. Grune, T. Jung, K. Merker, K.J. Davies, Decreased proteolysis caused by protein
aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and ‘aggresomes’ during
oxidative stress, aging, and disease, Int. J. Biochem. Cell Biol. 36 (2004) 2519–2530.
[200] U. Tomaru, S. Takahashi, A. Ishizu, Y. Miyatake, A. Gohda, S. Suzuki, A. Ono, J. Ohara,
T. Baba, S. Murata, et al., Decreased proteasomal activity causes age-related pheno-
types and promotes the development of metabolic abnormalities, Am. J. Pathol.
180 (2012) 963–972.
[201] N. Chondrogianni, I. Petropoulos, C. Franceschi, B. Friguet, E.S. Gonos, Fibroblast
cultures from healthy centenarians have an active proteasome, Exp. Gerontol. 35
(2000) 721–728.
[202] V.I. Perez, R. Buffenstein, V.Masamsetti, S. Leonard, A.B. Salmon, J. Mele, B. Andziak,
T. Yang, Y. Edrey, B. Friguet, et al., Protein stability and resistance to oxidative stress
are determinants of longevity in the longest-living rodent, the naked mole-rat,
Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 3059–3064.
[203] A.B. Salmon, S. Leonard, V. Masamsetti, A. Pierce, A.J. Podlutsky, N. Podlutskaya, A.
Richardson, S.N. Austad, A.R. Chaudhuri, The long lifespan of two bat species is cor-
related with resistance to protein oxidation and enhanced protein homeostasis,
FASEB J. 23 (2009) 2317–2326.
[204] Z. Ungvari, A. Csiszar, D. Sosnowska, E.E. Philipp, C.M. Campbell, P.R. McQuary, T.T.
Chow, M. Coelho, E.S. Didier, S. Gelino, et al., Testing predictions of the oxidative
stress hypothesis of aging using a novel invertebrate model of longevity: the
giant clam (Tridacna derasa), J. Gerontol. A Biol. Sci. Med. Sci. 68 (2013) 359–367.
[205] Q. Chen, J. Thorpe, J.R. Dohmen, F. Li, J.N. Keller, Ump1 extends yeast lifespan and
enhances viability during oxidative stress: central role for the proteasome? Free
Radic. Biol. Med. 40 (2006) 120–126.
[206] A. Tonoki, E. Kuranaga, T. Tomioka, J. Hamazaki, S. Murata, K. Tanaka, M. Miura,
Genetic evidence linking age-dependent attenuation of the 26S proteasome with
the aging process, Mol. Cell. Biol. 29 (2009) 1095–1106.
[207] U. Kruegel, B. Robison, T. Dange, G. Kahlert, J.R. Delaney, S. Kotireddy,M. Tsuchiya, S.
Tsuchiyama, C.J. Murakami, J. Schleit, et al., Elevated proteasome capacity extends
replicative lifespan in Saccharomyces cerevisiae, PLoS Genet. 7 (2011) e1002253.
